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Abstract 
Cardiovascular disease is one of major causes leading to death in the world. 
Previous studies suggest that soybean may be beneficial in preventing cardiovascular 
disease. It was proposed that genistein and its glycosides, which are present in 
soybean, might be responsible for this health benefit. However, up to now, there 
have been no studies about the chemical composition and health benefits of soy 
leaves even though soy leaves are abundantly available. 
In the present study, the chemical composition and some health benefits of soy 
leaves were investigated. By using high performance liquid chromatography 
(HPLC), mass spectrometry (MS) and nuclear magnetic resonance (NMR), six 
different kaempferol glycosides were identified and isolated from soy leaves. They 
are named as kaempferol-3-0-a-L-rhamnopyranosyl( 1 ->2)-P-D-glucopyranosyl 
(1 ->6)-p-D-galactopyranoside, kaempferol-3-0-(2,6-di-0-a-rhamnopyranosyl)-p-
galactopyranoside, kaempferol-3-O-digalactopyranoside, kaempferol-3-0-
diglucopyranoside, kaempferol-3-0-a-L-rhaminopyranosyl( 1 
galactopyranoside and kaempferol-3-O-rutinoside. The amount of kaempferol 
glycosides present in soy leaves was 22.4 mg/g. It was shown that soy leaves also 
contained genistein and its glycosides, but the amount was lower than that in soybean 
(0.54 mg/g in soy leaves and 2.12 mg/g in soybean). 
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The effect of soy leaves on the ratio of non-high-density lipoprotein cholesterol 
(non-HDL-C) to high-density lipoprotein cholesterol (HDL-C) was studied in 
hamsters fed a high fat and high cholesterol diet. Supplementation of 3% soy 
leaves powder (SLP) or 3% soy leaves ethanol extract (SLEE) in their diet could 
significantly lower this ratio to 0.79 ± 0.11 in the SLP group (p <0.01 )，0.78 士 0.18 in 
the SLEE group (p <0.05) compared to that of the control (0.92 土 0.08). 
In the antioxidation experiments, Cu^^-mediated LDL oxidation and inhibition 
of erythrocyte haemolysis were used to assess the antioxidative ability of soy leaves 
and its kaempferol glycosides. Results indicated that soy leaves butanol extract 
possessed a weak antioxidative ability against the Cu'^-mediated LDL oxidation and 
all the six kaempferol glycosides showed no inhibition in this assay. However, 
significant inhibitions on erythrocyte haemolysis was observed in the soy leaves 
butanol extract and all the kaempferol glycosides were inhibitory in a dose-
dependent manner. 
In the blood vessel relaxing experiments, soy leaves butanol extract relaxed 
artery rings pre-constricted by 9,ll-dideoxy-ll,,Vepoxy-methanoprostaglandin F^, 
(U46619) or [5Z,9„,ll„,13E,15S]-9,ll,15-trihydroxyprosta-5,13-dienoic acid ( P G F J 
in a dose-dependent manner. None of the kaempferol glycosides affected vessel 
tension induced by U46619. Results suggested that an active vasorelaxant other than 
iii 
the kaempferol glycosides were presented in soy leaves. 
In the last part of this study, female Sprague-Dawley rats were used as an 
animal model to determine the effect of soy leaves on tumor induction. 
Supplementation of 3% soy leaves powder in the diet could neither decrease the 
incidence rate nor the number of tumors induced by dimethylbenz[a]anthracene 
(DMBA). 
In conclusion, soy leaves may possess some beneficial effects in humans 
through the actions of modifying the lipoprotein profile to lower risk of 
cardiovascular disease, scavenging of the free radicals to decrease the oxidative 
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1.1 History of soybean 
The rich history of the soybean {Glycine max L. Merr.) began over five thousand 
years ago on the windy plains of eastern Asia. According to the Chinese tradition, 
soybeans were one of the five sacred crops named by Chinese emperor Sheng-Nung. 
Historians maintained that Sheng-Nung mentioned soybeans in his Ben Tsao Gang 
Mu, written in the year 2838 B.C. By 300 B.C., soybeans and millet were always 
mentioned in ancient texts as the two major food crops in northern China. 
Once the soybean was cultivated by Chinese farmers, it spread gradually from 
the northern part to the southern part of China. It was then spread into Korea, Japan, 
Southeast Asia and Europe. 
Soybeans yield more usable protein per acre than does any other crop and far 
more inexpensive protein than do animal foods. In China, with its shortage of 
pasture and arable farm land, nutrient-rich soybeans are an ideal food. Also, the 
Buddhist commitment to vegetarianism has led monks to create soy-based meat 
substitutes. 
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1.2 Health benefits of soybean 
Recently, the health effects of soybean have been extensively investigated. 
The growing evidence has shown that soybean may play important roles in the 
prevention of certain cancers (Kennedy 1998; Lamartiniere et al 1998; Thiagarajan 
et al 1998; Wei et al 1998; Wu et al 1998; Pollard and Wolter 2000), reduction of 
the risk of osteoporosis (Alekel et al. 1998; Arjmandi et al 1998 and Williams et al. 
1998) and heart disease (Huff et al. 1982; Wilcox et al 1995; Anthony et al 1996; 
Balmir et al 1996; Anthony et al. 1998; Nilausen and Meinertz 1998; Palacio et al. 
1998; Potter et al. 1998a and 1998b; Wilson et al. 1998; Wong et al. 1998; Anderson 
et al 1999; Ho et al. 2000 and Merz-Demlow et al 2000). These health benefits of 
soybean are believed due to isoflavones, which are abundant in soybean seeds. 
1.3 Introduction to flavonoids 
Flavonoids are polyphenolic compounds that are ubiquitously present in foods of 
plant origin. Flavonoids are categorised into flavonols, flavones, flavanones， 
catechins and isoflavones. All of them are structurally-related to the parent 
compound, flavone (2-phenylbenzopyrone) (Figure 1.1). 
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1.4 Bioavailability of flavonoids from foods 
The absorption and subsequent distribution, metabolism and excretion of 
flavonoids in humans have not been extensively studied. Absorption of flavonoids 
from the diet was long considered to be negligible, as most flavonoids are present in 
foods bound to sugar as P-glycosides. Only free flavonoids without a sugar 
molecule, the so called aglycon, were considered to be able to pass the gut wall 
because no enzymes that can split these predominantly p-glycosidic bonds are 
secreted into the gut or present in the intestinal wall (Hollman et al 1995). 
However, micro-organisms in colon are indispensable for hydrolysis of the [3-
glycosidic bonds (Kuhnau 1976 and Hollman and Katan 1999). Hollman et al 
(1995) showed that absorption of orally administered quercetin aglycon was 24%, 
whereas the absorption of quercetin glycosides from onions was much higher (52%), 
and the absorption of pure quercetin rutinoside was 17%. This study showed that 
humans absorb appreciable amounts of quercetin and that absorption of glycosides in 
the small intestine is possible. Andlauer et al (2000) showed that genistin, the 
glycoside of genistein, was partly absorbed without previous cleavage of the p-
glycosidic bond. Other studies showed similar results that the glycosides of 
quercetin had been found in human plasma (Paganga and Rice-Evans 1997). These 
studies indicate that flavonoid glycosides may be able to enter the human serum and 
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exert their effect directly. It has been estimated that humans consume 
approximately one gram of mixed flavonoids per day (Pierpoint 1986). 
1.5 Pharmacological effects of flavonoids and their glycosides 
In recent years, the flavonoids and their glycosides have attracted much 
attention in relation to their physiological and biological properties, such as a 
anticarcinogenic, antioxidative, cardioprotective, osteoprotective, neuroprotective 
and antiangiogenic. 
1.5.1 Anticarcinogenic activity 
Some studies have examined the anticarcinogenic activity of flavonoids 
(Peterson and Barnes 1996; Wei et al 1998; Denis et al 1999;Griffiths et al 1999; 
Dimas et al 2000; Mukhtar and Ahmad 2000; Steele et al. 2000). Isoflavones，a 
kind of flavonoids which are rich in soybean, are dietary components of plant origin 
with weak estrogenic activity (Kuiper et al. 1998). Epidemiologic data indicate that 
higher intakes of soy protein are associated with a lower rate of breast cancer (Lee et 
al. 1991; Messina et al 1994; Wu et al 1998). These epidemiologic data were 
supported by the observations that genistein decreased development of breast tumors 
in experimental animals and slowed the growth of human breast cancer cells in vitro 
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(Barnes 1995a). In vitro studies showed that genistein inhibited both estrogen and 
growth factor simulated proliferation of human breast cancer lines MCF-7, T47D 
ER+ and T47D ER" in culture with IC50 values ranging from 7.0 to 9.4 ^iM/mL 
(Peterson and Barnes 1996). Breast cancer growth is regulated by estrogen and 
peptide growth factors, such as epidermal growth factor (EGF), the receptor of which 
has intrinsic protein tyrosine kinase (PTK) activity. Akiyama et al (1987) showed 
that genistein could act as a specific inhibitor of PTK. Therefore, genistein may 
block mammary epithelial cell growth by interfering with signal transduction events 
stimulated by estradiol or growth factors. Setchell et al. (1984) suggested that 
genistein inhibited tumor cell growth by an antiestrogenic mechanism through 
competition with Ej for occupancy of the estrogen receptor (ER). 
Genistein was also shown to inhibit 7, 12-dimethylbenz[a]anthracene (DMBA) 
induced and 12-0-tetradecanoyl phorbol-13-acetate (TPA) promoted skin 
carcinogenesis in mice (Wei et al. 1998). 
Dimas et al (2000) showed that kaempferol glycosides exhibited a cytotoxic 
activity against human leukaemic cell lines CCRF-CEM, H33AJ-JA13, HUT 78, H9 
(T cells)，NAMALWA, JIYOYE，CCRF-SB, K562 and U937 with I Q � v a l u e s 
ranging from 6.5 to 30.7 mg/mL. 
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Figure 1.1 Chemical structures of some naturally occurring flavonoids. 
Substituent(s) at position:  
Flavonoid 5 6 7 8 T 3， 4， 5’ 
Flavones 
Apigenin OH OH OH 
Chrysin OH OH 
Tangeretin OCH3 OCH3 OCH3 OCH3 OCH3 OCH 
Nobiletin OCH3 OCH3 OCH3 OCH3 qCH OCH 
Flavonols ^ ^ 
Kaempferol OH OH OH 
Quercetin OH OH OH OH 
Galangin OH OH 
Fisetin OH OH OH 
Myricetin OH OH OH OH OH 
Morin OH OH OH OH 
Flavanones 
Naringenin OH OH OH 
Hesperetin OH OH OH OCH 
Isojlavones ^ 
Biochanin A OH OH OCH 
Genistein OH OH OH ^ 
Daidzein OH OH 
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1.5.2 Antioxidative activity 
Free radicals can induce oxidation of compounds such as lipids, proteins and 
even DNA single-strand breakage. The damage to biosystem is one of the major 
processes that contributes to degenerative diseases such as cancer, cardiovascular 
disease and aging. 
Antioxidant is a compound capable of inhibiting oxygen-mediated oxidation of 
diverse substrates, from simple molecules to polymers and complex biosystem. 
There are two types of antioxidants. The first type inhibits formation of free 
radicals, which may initiate oxidation. In most cases they are chelators of metal 
ions. The second type inhibits free-radicals chain-propagation reactions. 
Flavonoid is a kind of natural antioxidants which exhibit antioxidative and free 
radical scavenging activities. Studies showed that flavonoids can inhibit LDL 
oxidation and may be able to attenuate atherosclerosis (Aviram and Fuhrman 1998; 
Kerry and Abbey 1998; Zhu et al, 1999，2000). 
Apart from antioxidative ability of flavonoids in LDL, Asgary et al. (1999) 
showed that kaempferol could inhibit non-enzymatic glycosylation of amino group 
of lysine residue in haemoglobin which is usually caused by high glucose 
concentration in diabetes. These haemoglobin glycosylation is an oxidative 
reaction�therefore, antioxidant can be able to prevent this damage on haemoglobin. 
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And Noroozi et al (1998) demonstrated that flavonoids are also effective in 
preventing DNA damage on human lymphocytes. The effective dose that would 
result in a 50% reduction in oxidative damage (ED50) for kaempferol, quercetin and 
vitamin C were 104 ^mol/L, 40 i^moVL and 233 mmol/L from 100 |imol H2O2 /L 
respectively. They showed that flavonoids exhibited a higher antioxidative effect 
that vitamin C. Mitchell et al (1998) showed that the antioxidative capacity of 
kaempferol and quercetin were higher than vitamin C as determined by trolox 
equivalent antioxidant capacity (TEAC) and ferric reducing ability of plasma (FRAP) 
assay. 
The antioxidative activity of flavonoids may be related to the hydorxyl groups 
in the phenolic rings to produce a phenoxyl radical (Figure 1.2). The reduction 
potential of these groups are influenced by the number and their positions on the 
molecule. Noroozi et al. (1998) showed that the aglycons quercetin, kaempferol, 
luteolin and myricetin had a greater antioxidative capacity than do the conjugate 
flavonoids. The high reductive capacity of kaempferol in ESR and FRAP assay 
may due to the presence of the 4，-0H on the B-ring and the 3-OH on the C-ring 
(Figure 1.1) which are connected via the 71-orbital system and interact synergistically. 
The antioxidative activities of these flavonoids may change as a result of 
solvent effects and pH which can influence the state of protonation or deprotonation 
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of the hydroxyl groups. Therefore, the antioxidative activity of flavonoids may 
differ significantly in different model systems depending on the reduction potentials 
of the hydroxyl moieties relative to that of the oxidizing radical, or transition metal 
ion, used in the system (Mitchell et al 1998). 
In the microsomal system, another important factor that determines the 
antioxidative efficiency of these flavonoids is their ability to partition between 
aqueous and lipid phases. 
1.5.3 Cardioprotective activity 
Epidemiological data suggest that dietary flavonoid intake is inversely 
associated with mortality from coronary heart disease (Hertog et al 1993; Arai et al 
2000; Ho et al. 2000). 
Apart from the antioxidative effect of flavonoids that can decrease the chance of 
atherosclerosis, flavonoids may also be beneficial in improving plasma lipid profile. 
Soy isoflavone decreased non-high density lipoprotein cholesterol (non-HDL-C) and 
increased HDL-C (Anthony et al 1996, 1998; Merz-Demlow et al 2000). The 
effect of lowering low-density lipoprotein cholesterol (LDL-C) and increasing HDL-
C by isoflavones may be due to their weak estrogenic effect. These isoflavones can 
bind to estrogen receptors (Kuiper et al 1998) and share the LDL reducing and HDL 
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increasing effects of human estrogen (Lilley et al. 1998; Westerveld 1998; Godsland 
2001). The mechanism of how estrogen reduces serum LDL and increase HDL is 
still unclear but it is proposed that estrogen induces the LDL-receptor activity and 
increases the rate of LDL elimination in the liver. 
1.5.4 Osteoprotective activity 
Arjmandi et al (1998a, 1998b) showed soy isoflavones can significantly 
increase the bone density of ovarian hormone-deficient rats. They suggested that 
the serum alkaline phosphatase activity (ALP), an index of bone formation，tended 
to be higher in soy-fed animals, indicating a positive effect on bone formation. 
Another proposed mechanism is that genistein can act as an inhibitor of tyrosine 
kinases which can directly modulate osteoclastic acid sectretion (Akiyama et al. 
1987). This acid secreted onto the bone matrix can dissolve the bone mineral. 
This process is under complex control related to the maintenance of serum calcium 
activity and bone strength, disorders of which may cause osteoporosis. Thus, 
substances influencing bone resorption may be a potential antiosteoporotic agents 
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1.5.5 Neuroprotective activity 
Alzheimer's disease (AD) is one of the major neurodegenerative diseases. 
Amyloid P protein (Ap), the major protein component of senile plaque, can elicits a 
toxic effect on neurons. It has been suggested to play an important role in 
pathogenesis of AD. Wang et al (2001) showed that 50 kaempferol and 
apigenin decreased the Ap-induced cell death by 81.5% and 49.2% respectively. 
However, quercetin and luteolin failed to protect neurons. They suggested that the 
substitution of hydroxyl group at C-3，position severely impaired the neuroprotective 
ability of kaempferol. 
1.5.6 Antiangiogenic activity 
Angiogenesis, the generation of new capillaries, is virtually absent in the 
healthy adult organism and is restricted to a few conditions including wound healing 
and the formation of corpus luteum, endometrium, and placenta. However, if 
angiogenesis is not tightly regulated, it is obligatory for the growth and progression 
of solid cancers. Fotsis et al. (1993) showed that genistein was a potent inhibitor of 
endothelial cell proliferation and in vitro angiogenesis at concentrations giving half-
maximal inhibition of 5 and 150|aM, respectively. Another studies showed that 
flavonoid may inhibit angiogenesis through the inhibition on the secretion of a 
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primary angiogenic cytokine, vascular endothelial growth factor (VEGF), by human 
prostate and breast cancer epithelial cells (Jiang et al. 2000). Therefore, flavonoids 
may inhibit the growth and progression of solid cancers through the inhibitory effect 
of angiogenesis. 
1.6 Soybean leaves 
To my best knowledge, there was no study about the health effects of soy leaves 
and its chemical composition. Soy leaves not only contain isoflavones but also 
contain some valuable flavonoid glycosides (details will be discussed in Chapter 2). 
Therefore, the health benefits of soy leaves deserve further investigation. In the 
present study, the biological activities of soy leaves and its different flavonoid 
glycosides were examined. 
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Chapter 2 
Isolation and purification of kaempferol 
glycosides and genistin in soy leaves 
2.1 Introduction 
Flavonoids and their glycosides are polyphenolic compounds which are widely 
distributed in fruits, vegetables and nuts. Naturally occurring flavonoids are 
classified as flavones, flavonols, flavanones, isoflavones and catechins. They are 
structurally-related to the parent compound, flavone (2-phenylbenopyrone). It has 
been estimated that humans consume approximately Ig of mixed flavonoids per day 
(Pierpoint 1986). 
Flavonoids have many beneficial effects including being antioxidative (Arora et 
al 1998; Kerry and Abbey 1998; Mitchell et al 1998; Noroozi et al. 1998 and Zhu et 
al 2000)，anti-carcinogenic (Akiyama et al 1987; Fotsis et al 1993 and Peterson 
and Barnes 1996)，anti-atherosclerosis (Anthony et al. 1998)，and relaxative to blood 
vessel (Mishra et al. 2000; Figtree et al 2000). It is well known that soybean 
contains a large amount of isoflavones，however, up to date, there is no study that has 




The present study was to isolate and purify the known and unknown flavonoids 
and their glycosides from soy leaves {Glycine max L. Merr). Their antioxidative 
and relaxing effects in rat carotid artery rings were then examined. 
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2.3 Materials and Methods 
2.3.1 Extraction and isolation 
23,1.1 Preparation of soy leaves butanol extract 
Dried soy leaves (3 kg) were extracted with 18 L 70% ethanol three times at 50 
°C. Ethanol was evaporated under vacuum to yield 1550 g ethanol extract, which 
was then dissolved in 2 L distilled water. Then the ethanol extract was partitioned 
with chloroform in a ratio of 1:1 for three times. The chloroform fraction was dried 
down under vacuum to yield 98 g chloroform extract. The remaining ethanol extract 
was further partitioned with butanol in a ratio of 1:1 for three times. The butanol 
and water fractions were dried down under vacuum to yield 110 g butanol extract and 
1280 g water extract. 
2.3,1.2 Preparation of kaempferol glycosides from soy leaves butanol extract 
In brief, 105 g soy leaves butanol extract was fractionated in a column packed 
with Sephadex LH-20 (100 |iM, Pharmacia Fine Chemical Co., Ltd., Germany) and 
eluted with 4.4 L absolute methanol (400 mL each time) to give rise to eleven 
fractions (SI to Sll) . Fractions SI, S2, S3 and S l l contained mainly sugars, 
organic acids and some other components with no UV absorption, while S4 - SIO 
contained mainly a mixture of glycosides. The total weight of the fractions S4 to SIO 
16 
was 81 g. Each fraction of S4- SIO was then loaded onto a Sephadex LH-20 
column. For S4, S5 and S8, pure methanol was used, while for S6, S7, S9 and SIO, 
40% acetone was used to elute the column. The elutes were monitored using a 
HPLC equipped with a UV detector. These fractions containing flavonoids or 
glycosides were then loaded onto a CI8 HPLC preparative column (Hypersil ODS, 
250 X 22mm, 10 |Lim, Alltech, Deerfield, IL, USA) and eluted with water and 
acetonitrile，leading to purification of six compounds. The chemical structures and 
the molecular weights of these glycosides were identified using their ultraviolet (UV), 
infrared (IR)，mass, iH-NMR and i^C-NMR spectrum. The purity of these 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































 chart for the isolation of the flavonoids and their glycosides from





2.3.2 High performance liquid chromatography (HPLC) analysis 
2.3.2.1 Sample preparation for the HPLC analysis 
All wet samples were freeze-dried before the HPLC analysis. One gram of 
dried，finely ground samples was placed in a 100 mL conical flask containing 40mL 
methanol, 20 mL 0.1 N HCl and 0.2 mL flavone (11.25 mM in methanol). The 
mixture was sonicated for 10 minutes and then stirred at room temperature for 2 
hours using a magnetic stirrer. Extractants were centrifiiged at 850 g for 10 minutes. 
The supernatant of sample was filtered through a 0.45 |Lim PTEE filter 
[poly(tetrafluoroethylene), Alltech Associates Inc., Deerfield, IL]. The supernatant 
was transferred into a 1.5 mL sample vial (Hewlett Packard, Palo Alto, CA, USA) 
and then subjected to HPLC analysis. 
2.3.2.2 HPLC analysis 
All the flavonoids and their glycosides were analyzed using a Hewlett Packard 
series 1100 HPLC (Hewlett Packard, palo alto, CA, USA) equipped with a binary 
pump delivery system (G1322A) and a diode array detector (G1946A). 
In brief, 10 |aL of the supernatant was loaded onto a CI 8 column (Hypersil ODS, 
4.6 X 250 mm, 5 |iM, Waters, Ireland) through an autosampler (G1313A). The 
diode array detector was set from 200 to 400 nm, and the eluting components were 
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monitored at 260 nm. The quantitative analysis of the flavonoids and their 
glycosides were carried out according to the method of Wang and Murphy (1994) 
with some modifications. The mobile phase consisted of 1% acetic acid in water 
(v/v) (solvent A) and acetonitrile (solvent B). After injection of the sample, solvent 
B was increased from 10 to 20% in 40 min and then increased from 20 to 100% in 
the next 30 min. The flow rate was maintained at 0.8 mL/min. Two typical HPLC 
chromatograms of soybean and soy leaves were shown in Figures 2.2 and 2.3 
respectively. 
20 
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2J.2.3 Quantification of the flavonoids and their glycosides 
The flavonoids and their glycosides were quantified by comparing area 
responses with those of authentic standards or the compounds purified by the method 
as described in part 23,1,2. Authentic standards for genistein, daidzein and 
kaempferol with a purity higher than 98% were obtained from Sigma Chemical 
Company (St. Louis, MO, USA). The concentrations of malonyl and acetyl 
glycosides of genistein and daidzein were calculated from the curves for 
corresponding p-glycosides, corrected for molecular weight differences since the 
molar extinction coefficient of the esterified isoflavone is similar to that of the P-
glycosides (Barnes et al. 1994). 
2.3,2,4 Change in flavonoids and their glycosides in soy leaves 
Soy leaves were planted in Meng County in Henan in China in the period from 
June to September. Three different batches of soy leaves samples were collected at 
the end of each month. The flavonoids and their glycosides were determined by the 
method described in part 2,3,2,1- 2,3,13. 
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2.4 Results 
The structures of six unknown compounds were identified by studying their 
various spectra of UV, IR, Mass, and '^C-NMR. The characteristics of each 
compound were described below and the structures were illustrated in Figures 2.4 
and 2.5. 
2.4.1 Compound 1 
Yellow amorphous powder, m.p. 199-201�C，[a]=-71.87 (c0.064, MeOH), 
C33H40O2�. w/z: 757 [M+\] \ 611 [M-rhamnosyl+l]+，499[M-rhamnosyl-glucosyl+l]+ 
MeOH 
and 287 [M-rhamnosyl-glycosyl-galactosyl+1]^ ； UV ？tMax nm: 266，300sh, 348; IR 
KBr 
DMaxcm-1: 3408，1658, 1608, 1508, 1361，1207, 1178，1072, 889, 893，814; 'H and '^C 
NMR. 
2.4.2 Compound 2 
Yellow amorphous powder, m.p. 203-205�C，[a]二 -87.8 (C0.660, MeOH), 
C33H4GO19 m/z: 741 [M+l]+’ 595 [M-rhamnosyl+l].’ 499 [M- 2x rhamnosyl+l]+， 
287 [M- 2x rhamnosyl-galactosyl+1]^; UV nm: 266, 300sh, 349; IR UM^xcm"': 
3361，1660, 1610，1508, 1450, 1360, 1209，1178，1136，1051，978，837, 812; 'H and 
"C NMR. 
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2.4.3 Compound 3 
Yellow amorphous powder, m.p. 196-198�C，[a]= -23.7 (c0.050, MeOH), 
C27H3oO,6 . m/z: 611 [M+\]\ 449 [M-galactosyl+l]+，287 [M- 2x galactosyl+l]+， 
MeOH KBr 
u v X Max nm: 267, 300sh, 352; IR UMaxcm'': 3330，1660, 1606，1498’ 1361，1279, 
1257, 1207, 1078，1018, 889, 841; >H and ' 'C NMR. 
2.4.4 Compound 4 
Yellow amorphous powder, m.p. 198-200�C，[a]= -23.7 (c0.050，MeOH), 
C27H3oO,6. m/z: 611 [M+l]+，449 [M-glucosyl+l].，287 [M- 2x glucosyl+l]+; UV 
MeOH KBr 
入 Max nm: 266，315sh, 351; IR U M a x c m ': 3377, 1657, 1606, 1504，1361，1281，1211, 
1178, 1080, 1030，887，841; ^H and '^ C NMR. 
2.4.5 Compound 5 
Yellow amorphous powder, m.p. 228-230�C，[a]^ -17.28 (c0.045，MeOH), 
MeOH KBr 
C27H30O15. m/z: 595 [M+l]+; UV X,Max nm: 265, 300sh, 350; IR UMax cm"': 3410， 
1655, 1606，1500, 1360, 1209，1178，1084，1057, 841, 841; 'H and '^C NMR. 
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2.4.6 Compound 6 
Yellow needle shaped crystal, m.p. 182-185�C，Cj^HjoOij m/z 595 [M+l]+; 
MeOH KBr 
UV ^Max nm: 266, 310sh, 350; IR UMax cm"': 3408, 1655, 1606，1506，1450, 1360, 
1211，1178, 1065, 1014，885, 839，808; 'Hand ' 'CNMR. 
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Table 2.1 UV absorptions of compound 1-6 (人 x^) in different solutions 
MeOH NaOMe AlO^ AICI3/ NaOAc N a O A c / ~ 
HCl H3BO3 
Compound 1 ^ ^ m ^ ^ 
300sh 323 305 305 308 300sh 
348 393 352 348 382 353 
399 399 
Compound 2 266 274 275 275 267 267 
300sh 323 303 305 301 301sh 
349 393 347 350 365 348 
397 399 
Compound 3 267 275 274 275 275 268 
300sh 326 304 304 312 296 
352 402 351 347 392 351 
398 398 
Compound 4 266 275 272 275 274 266 
315sh 326 305 303 309 300sh 
351 402 350 346 389 355 
399 399 
Compound 5 265 275 274 275 274 266 
300sh 326 305 303 305 298 
350 402 351 351 383 351 
397 397 
Compound 6 266 275 274 274 274 266 
310sh 326 303 304 315 310sh 
350 402 352 350 394 353 
398 397 
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Table 2.2 NMR spectra of compound 1-6 in DMSO-d^  
Compound 1 Compound 2 Compound 3 Compound 4 Compound 5 Compound 6 Kaempferol 
3-OH - - - - - - 9 37 
5-OH 12.60 12.68 - 12.58 - 12.55 12.47 
6 6.18(s) 6.16(s) 6.17(dl.5) 6.18(d2.1) 6.11(s) 6.20(d2.1) 6.18(d3.0) 
7-OH - - - 10.20 - 10.83 10.77 
8 6.40(s) 6.38(s) 6.39(dl.5) 6.40(dl.8) 6.32(s) 6.40(d2.1) 6.43(d3.0) 
2' 6' 8.05(d) 8.03(d9.0) 8.06(d7.0) 8.03(d9.0) 8.03(d9.0) 8.00(d9.6) 8.03(dl5) 
3' 5' 6.84(d) 6.85(d8.0) 6.86(d7.0) 6.89(d9.0) 6.85(d9.0) 6.87(d9.6) 6.91(dl5) 
4'-0H - - - 10.20 - 10.10 10.10 
1" 5.56(d8.0) 5.55(d8.0) 5.34(d7.5) 5.36(d7.2) 5.27(d7.5) 5.32(d7.0) -
2"-6" 2.81- 3.32- 2.91- 2.80- 3.01- 3.15- -
3.80(m) 4.36(m) 4.06(m) 3.38(m) 3.62(m) 3.69(m) 
1"' 5.04(S) 5.04(S) 3.77(d6.5) 4.04(d7.5) 4.4(s) 5.07(d8.0) -
2"'-5"' 3.33- 3.10- 2.84- 2.80- 3.09- 3.42- -
3.7 l(m) 3.74(m) 3.95(m) 3.38(m) 3.62(m) 4.08(m) 
6"' 0.77(d6.0) 1.04(3H 3.71(d3.0) - 1.05(d6.3) 0.98(d6.3) -
d6.0) 3.38(d3.0) 
1"" 4.02(d8.0) 5.04(s) -
2""-6"" 3.12- - - - - . 
3.77(m) 
6"" 3.33(m) 0.78(3H -
2.96(d8.5) d6.0)  
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Table 2.3 ^^ C NMR spectra data of compound 1-6 in DMSO  
Compound 1 Compound 2 Compound 3 Compound 4 Compound 5 Compound 6 kaempferol 
2 156.20 156.35 156.34 156.29 156.42 156.26 146.60 
3 132.71 132.67 133.20 133.05 133.01 133.0 135.48 
4 177.29 177.30 177.32 177.11 176.78 177.12 175.56 
5 161.19 161.24 161.16 160.95 160.84 160.97 160.48 
6 98.89 98.67 98.97 98.64 99.93 98.60 98.08 
7 164.46 164.01 165.15 164.07 166.55 163.87 163.64 
8 93.76 93.68 93.85 93.66 93.93 93.63 93.37 
9 156.38 156.35 156.50 156.29 155.96 156.62 155.95 
10 103.90 103.98 103.63 103.02 102.86 103.86 102.92 
r 120.90 120.91 120.84 120.72 120.66 120.73 121.51 
2' 130.83 130.82 130.94 130.79 130.71 130.71 129.34 
3' 115.07 115.07 115.08 114.96 114.92 114.94 115.29 
4' 159.90 159.85 159.08 159.70 159.82 159.66 158.96 
5' 115.07 115.09 115.08 114.96 114.92 114.94 115.29 
6' 130.83 130.82 130.94 130.79 130.71 130.71 129.34 
1 � 102.90 98.97 102.89 103.87 102.21 101.20 
2� 74.80 74.83 71.11 74.03 71.83 74.10 
3� 73.62 73.80 73.75 76.18 73.39 76.27 
4� 68.43 68.53 69.87 69.66 68.21 69.86 
5� 73.23 73.33 76.59 76.49 72.94 75.66 
6� 67.08 65.14 67.15 67.94 65.24 66.82 
V" 100.58 100.08 103.63 100.92 99.25 100.65 
2"' 70.68 70.42 72.93 73.34 70.34 70.28 
3'" 70.59 70.58 73.27 76.49 70.55 70.52 
4'" 71.84 71.88 67.81 69.66 71.05 71.70 
5'" 68.18 68.18 76.59 76.49 67.94 68.19 
6'� 17.26 17.92 60.88 60.74 17.96 17.76 
1"" 98.70 100.58 
2"" 73.76 70.42 
3"" 76.58 70.58 
4"" 69.87 71.88 
5"" 76.58 68.28 
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2.4.7 Quantification of flavonoids in soybean and soy leaves 
The flavonoids in soybean and in soy leaves were quantified from the standard 
curves of their authentic standards or pure compounds (purified in part 2.3.1.2) with 
flavone as an internal standard (Table 2.4). 
2.4.8 Age-dependent changes in flavonoids and their glycosides 
The three different batches of soy leaves samples were collected from Meng 
county, Henan, China. Their flavonoids and their flavonoid glycosides in these soy 
leaves were determined and shown in Figure 2.6. It was found that total flavonoids 
and their glycosides reached highest at month 3. 
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Table 2.4 The compositions of flavonoids in soybean and in soy leaves (mg/g) 
Soybean Soy leaves 
Daidzin 0.32 土 0.02 ND 
Genistin 0.54 土 0.03 0.09 ± 0.02 
Malonyl-daidzin 0.98 ±0.19 ^ 
Malonyl-genisin 1.56 ±0.01 0.31 ±0.01 
Daidzein 0.02 ±0.01 ND 
Genistein 0.02 ±0.01 ND 
Compound 1 ND 0.32 ±0.01 
Compound 2 ^ 7.06 ±0.10 
Compound 3 m 1.08 ±0.06 
Compound 4 ND 0.88 ± 0.03 
Compound 5 5.04 ±0.14 
Compound 6 8.02 ±0.16 
Total 3.45 ±0.27 22.80 土 0.29 
Data are expressed as mean 土 S.D. (n=3) 
ND: Not detected 
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2.5 Discussion 
2.5.1 Compound 1 
Compound 1，was isolated as a yellow amorphous powder, m.p. 199-201 
[aJo -71.87 (cO.064，MeOH), with molecular formula C33H40O20 deduced from 'H 
NMR (Table 2.2), ' 'C NMR (Table 2.3) and mass spectrometry. The [M+l]+ peak 
at m/z 757 in the APCI-MS (Atmospheric Pressure Chemical Ionization- Mass 
Spectrometry), indicated the formula weight was 756. The APCI-MS spectrum of 
compound 1 revealed peaks at m/z 611 [M-rhamnosyl+l]+，m/z 499[M-rhamnosyl-
glucosyl+l]+ and m/z 287 [M-rhamnosyl-glycosyl-galactosyl+1 indicating 
compound 1 was a glycoside containing 3 different sugars. The 'H NMR signals 
due to the aglycon at 5 6.18 ppm (IH, s), 6 6.40 ppm (IH, s), 6 8.05 ppm (2H, d, J= 
8.5 Hz), 5 6.84 ppm (2H, d, J= 9 Hz), showed the characteristic pattern of 
kaempferol derivatives. From the '^C NMR spectrum, the downfield shift of C-3 by 
2.7 ppm, indicated the bonding site of the sugar group was at C-3 position (Markham 
et al. 1978). The HMBC (Heteronuclear Mutiple Bond Coherence) spectrum also 
showed important correlation between the H-1 [6 5.58 ppm] of the galactose and C-3 
[5 132.7 ppm] of the aglycon. This further proved that the glycosylation site was at 
C-3 position of the aglycon. The data of the UV spectrum (Table 2.1) indicated the 
presence ofhydroxyl groups at C-7 and C-5 positions (Hillis and Isoi, 1965). Acid 
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hydrolysis of compound 1 led to form a aglycon kaempferol. The sugars remained 
after acid hydrolysis were proved to be rhamnose, galactose and glucose by TLC 
(Thin Layer Chromatography) with their standards. 
From the ^^ C NMR spectrum, the C-2 of the galactose showed a downfield shift 
by 2 ppm, indicated the rhamnose was linked at C-2 position of the galactose. The 
C-6 of the galactose at 6 67.88 ppm performed a downfield shift by 6.2 ppm and the 
C-6 of the glucose at 5 60.87 ppm showed a (6->l) linkage between the galactose 
and the glucose. 
Compound 1 was deduced as kaempferol-3-O-a-L-rhamnopyranosyl (l->2)-p-
D-glucopyranosyl (1 ->6)-p-D-galactopyranoside (Figure 2.4). 
2.5.2 Compound 2 
Compound 2，was isolated as a yellow amorphous powder, m.p. 203-205 [a] 
20 
d-87.8 (CO.660, MeOH), with a formula C33H400,9 deduced from 'H NMR (Table 2.2), 
"C NMR (Table 2.3) and mass spectrometry. The [M+l]+ peak at m/z 741 in the 
APCI-MS, indicated the formula weight was 740. The APCI-MS spectrum of 
compound 2 revealed peaks at m/z 595 [M-rhamnosyl+l]+，m/z 499 [M- 2x 
rhamnosyl+l]+ and m/z 287 [M- 2x rhamnosyl-galactosyl+1 Acid hydrolysis of 
compound 2 led to form a aglycon kaempferol. The sugars were proved to be 
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rhamnoses and glucose by TLC with their standards. The results of the UV 
absorption spectrum, 'H NMR and "C NMR were compared with the data from Fico 
et al (2000), proving that compound 2 was kaempferol-3-0-(2,6-di-0-a-
rhamnopyranosyl)-P-galactopyranoside (Figure 2.4). 
2.5.3 Compound 3 
Compound 3，was isolated as a yellow amorphous powder, m.p. 196-198�C， 
[a]2�D -23.7 (cO.050，MeOH), with molecular formula C27H30O16 deduced from 
NMR (Table 2.2), '^ C NMR (Table 2.3) and mass spectrometry. The [M+l]+ peak 
at m/z 611 in the APCI-MS, indicated the molecular weight was 610. The APCI-
MS spectrum of compound 3 revealed peaks at m/z 449 [M-galactosyl+l]+ and m/z 
287 [M- 2x galactosyl+l]+. The data of the UV spectrum (Table 2.1) showed the 
presence of hydroxy 1 groups at C-5 and C-7 positions (Hillis and Isoi, 1965). From 
the 13c NMR spectrum, the upfield shift of C-3 by 2.2 ppm, indicated the 
glycosylation site was at C-3 position (Markham et al. 1978). The C-6 of the 
galactose showed a downfield shift by 6.3 ppm, showed a (l->6) linkage between the 
two galactoses. Acid hydrolysis of compound 3 led to form a aglycon kaempferol. 
The sugars after acid hydrolysis were proved to be galactose by TLC with the 
standard galactose. Compound 3 was deduced as kaempferol-3-0-
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digalactopyranoside (Figure 2.4). 
2,5.4 Compound 4 
Compound 4, was isolated as a yellow amorphous powder, m.p. 198-200�C， 
MI 一 2 3 . 7 (c0.050, MeOH), with molecular formula C27H30O16 deduced from 
NMR (Table 2.2)，''C NMR (Table 2.3) and mass spectrometry. The [M+l]+ peak 
at m/z 611 in the APCI-MS, indicated the molecular weight was 610. The APCI-
MS spectrum of compound 4 revealed peaks at m/z 449 [M-glucosyl+l]+ and m/z 287 
[M- 2x glucosyl+l]+. Compound 4 showed similar values of UV spectrum with 
compound 3, indicated that compound 4 has a similar structure with compound 3. 
From the '^C NMR spectrum of compound 4，the C-6，，，of the glucose showed a 
downfield shift by 6.2 ppm, indicated a (1-^6) linkage between the two glucose 
molecules. After acid hydrolysis of compound 4, a aglycon kaempferol was formed. 
The sugars after acid hydrolysis were proved to be glucose by TLC with the standard 
glucose. Compound 4 was deduced as kaempferol-3-O-diglucopyranoside (Figure 
2.5). 
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2.5.5 Compound 5 
Compound 5, was isolated as a yellow amorphous powder, m.p. 228-230 
[a]l -17.28 (cO.045，MeOH), with molecular formula CjyHjoOij deduced from 'H 
NMR (Table 2.2), '^C NMR (Table 2.3) and mass spectrometry. The [M+l]+ peak 
at m/z 595 in the APCI-MS, indicated the molecular weight was 594. The NMR 
signals due to the aglycon at 5 6.11 ppm (IH, s), 6 6.32 ppm (IH, s), 6 8.03 ppm (2H, 
d，J= 9.0 Hz) and 5 6.85 ppm (2H, d, J= 9.0 Hz), showed the characteristic pattern of 
kaempferol derivatives. 'H NMR also showed two anomeric protons signals at 
5 5.27 ppm (IH, d, J= 7.5 Hz) and 6 4.4 ppm (IH, s). Furthermore, the '^C NMR 
showed a upfield shift of C-3 by 2.4 ppm, these data indicated the presence of two 
sugar moieties in compound 5 and the bonding site of the sugar group was at the C-3 
position (Markham et al. 1978). The 'H NMR spectrum gave signals 6 1.05 ppm 
(3H，d，J= 6.3 Hz) indicated one of the sugar was rhamnose. '^C NMR showed 
another sugar was galactose. Also the '^C NMR showed the C-6 of the galactose 
shifted downfield by 5 ppm, indicated a (l->6) linkage between the rhamnose and 
the galactose. Acid hydrolysis of compound 5 yielded a aglycon kaempferol. The 
sugars after acid hydrolysis were proved to be rhamnose and galactose by TLC with 
their standards. Compound 5 was deduced as kaempferol-3-O-a-L-
rhamnopyranosyl (1 ^6)-P-D-galactopyranoside (Figure 2.5). 
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2.5.6 Compound 6 
Compound 6，was isolated as a yellow needle shaped crystal, m.p. 182-185�C, 
with molecular formula C27H30O15 deduced from 'H NMR (Table 2.2), '^C NMR 
(Table 2.3) and mass spectrometry. The [M+l]+ peak at m/z 595 in the APCI-MS, 
indicated the molecular weight was equal to 594. Acid hydrolysis of compound 6 
yielded a aglycon kaempferol. The sugars after acid hydrolysis were proved to be 
rhamnose and glucose by TLC with their standards. From the '^C NMR, the C-3 of 
the aglycon showed a upfield shift by 2 ppm, indicated the glycosylation site was at 
C-3 position (Markham et al. 1978). Also the '^C NMR showed the C-6 of the 
glucose shifted downfield by 6ppm, indicated a (1-^6) linkage between the 
rhamnose and the glucose. The results of the NMR and '^C NMR were 
compared with the data from Fico et al. (2000), proving that compound 6 was 
kaempferol-3-0-rutinoside (Figure 2.5). 
2.5.7 Age-dependent changes in flavonoids and their glycosides 
The present results showed that total flavonoids and their glycosides in the first 
month and the second month were almost similar. However, the total content of 
these flavonoids and their glycosides were increased by about 48% in the third month 
when compared with that in the second month. 
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Chapter 3 
Hypolipidemic effects of soy leaves in hamsters 
3.1 Introduction 
3.1.1 Different lipoproteins and their functions 
Most of the cholesterol in plasma is transported by 3 major lipoprotein classes: 
VLDL cholesterol (VLDL-C), LDL cholesterol (LDL-C), and HDL cholesterol 
(HDL-C) (Superko 2001). Triglyceride-rich VLDL, one of the major triglyceride 
carriers in the blood, is synthesized and secreted from the liver. After a series of 
interactions with the enzyme lipoprotein lipase, the particles become more dense and 
relatively cholesterol rich. An intermediate density lipoprotein (IDL) precedes the 
appearance of LDL, which is normally the greatest source of cholesterol transport 
among the lipoproteins. The role of LDL is for transporting cholesterol from liver 
to the peripheral tissues. In contrast to LDL, the HDL synthesized in liver is the 
main vehicle for the transfer of cholesterol from plasma and the peripheral tissues 
back to the liver for catabolism (Eckardstein et al. 1998，2001; Stein and Stein 1999； 
McNamara 2000). 
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3.1.2 Risk factors of cardiovascular disease 
Over the past 40 years, epidemiologic studies showed that blood levels of total 
and LDL-C are directly related to cardiovascular disease (LaRosa et al. 1990; 
Carleton et al 1991). Cholesterol accumulation in the artery is accompanied by the 
development of atherosclerosis (Brown and Goldstein 1986). However, high level 
of total cholesterol in plasma may not be absolutely related to the cardiovascular 
disease (Hamilton 1997). LDL is the major cholesterol carrier in the blood, its 
oxidation is related to the formation of atherosclerosis (Parhami et al 1993; Diaz et 
al 1997; Young et al. 2001) (The role of LDL oxidation on the formation of 
atherosclerosis will be discussed in Chapter 4). As the amount of LDL cholesterol 
in the blood increase, the chance of being oxidized will be increased. Therefore, the 
amount of LDL cholesterol present in the blood can be used as one of the index for 
the risk of cardiovascular disease (Hamilton 1997; Ballantyne 1998). 
Some other more precise indexes for the risk of cardiovascular disease are the 
ratios of LDL-C to HDL-C or non-HDL-C to HDL-C. Many studies showed that 
HDL-C was inversely related to the risk of cardiovascular disease (Backer et al. 1998; 
Boden et al 2000a, 2000b; Despres et al. 2000). This may be due to the reversal 
cholesterol transport of HDL from peripheral cells and plasma back to the liver for 
catabolism (Eckardstein et al. 1998, 2001; Kwiterovich 1998; Philips et al 1998). 
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As a result, the effect of reversal cholesterol transport of HDL can prevent the 
accumulation of cholesterol in plasma and decrease the chance of atherosclerosis. 
3.1.3 Animal model 
Golden Syrian hamster (Mesocricetus Auratus) is a common model for 
hypocholesterolemic and cholesterol metabolism studies (Sugiyama et al. 1995; 
Campos et al. 1998; Terpstra et al 1998; Trautwein et al 1998，1999; Ntanios and 
Jones 1999; Schneider et al 2000). Similar to that in humans, the major cholesterol 
carrier in hamster is LDL (Nistor et al. 1987). It was found that about 50% of 
hamster's plasma cholesterol occurs in the LDL fraction (Nistor et al 1987). Also 
hamsters are similar to humans in biliary sterol secretion (Spady and Dietschy 1984; 
Bocan and Guyton 1985). Rat is another common laboratory testing animal, 
however, they lack the cholesteryl ester transfer protein and are resistant to 
developing atherosclerosis due to high cholesterol feeding, while hamsters are like 
humans and are susceptible to atherosclerosis (Bok et al 1999). 
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3.2 Objectives 
The objective of the present study was to examine the hypolipidemic effect of 
soy leaves. Soybean has been shown to reduce plasma cholesterol in humans 
(Anthony et al 1998; Nilausen and Meinertz 1998; Potter et al 1998; Wong et al 
1998). However, the hypolipidemic effects of soy leaves have not been examined. 
In the present study, the hypolipidemic effects of soy leaves was investigated by 
using hamster as an animal model. 
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3.3 Materials and Methods 
3.3.1 Animals 
Male Golden Syrian hamsters were housed (3- 4 hamsters per cage) in an animal 
room at 25 °C with 12:12-h light-dark cycles. Fresh semi-synthetic diets were given 
daily, and uneaten food was discarded. Food intake was measured daily and body 
weight was recorded twice a week. The hamsters were allowed access to food and 
fluid ad libitum. 
Hamsters (125- 140 g) were randomly divided into 3 groups (n= 12). They 
were fed a semi-synthetic diet, with soy leaves powder (SLP) or soy leaves ethanol 
extract (SLEE) supplementation. The method described by Sanders & Sandaradura 
(1992) was modified and used to prepare the semi-synthetic diet. For the control 
group, diet was prepared by mixing the powdered ingredients (casein, 200 g; lard, 
100 g; coconut oil, 100 g; starch, 418 g; sucrose, 100 g; mineral mix, 40 g; vitamin 
mix, 20 g; DL-methionine, 1 g; and cholesterol, 1 g) with 200 mL gelatin solution 
(lOOg/L). For the second and the third group of hamsters, 3% by weight soy leaves 
powder (SLP) and the ethanol extract (SLEE) derived from 3% soy leaves were 
mixed with the control diet respectively before setting them in gelatin. Once the 
gelatin had set, the diet was cut into approximately 20 g cubic portions and stored 
frozen (-20 °C). All the fecal samples were collected from each cage of the 
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hamsters at the end of each week. At the end of 4 weeks, all the hamsters were 
sacrificed after overnight fasting. Blood was collected via the abdominal aorta. 
After clotting, the blood was centrifuged at 1500 g for 10 minutes and plasma was 
collected. The liver and perirenal adipose tissue were removed, washed with saline, 
and stored a t -80 °C. 
3.3.2 Serum lipid and lipoprotein determinations 
Serum total triacylglycerols (TG) and total cholesterol (TC) levels were 
determined using enzymatic kits (Sigma Chemical, St. Louis, MO, USA). High-
density lipoprotein cholesterol (HDL-C) was measured after precipitation of LDL 
and very low-density lipoprotein (VLDL) with phosphotungstic acid and magnesium 
chloride (Sigma). 
3.3.3 Determination of cholesterol in the liver and adipose tissue 
The liver (300 mg) or adipose tissue (300 mg) samples and 1 mg stigmastanol, 
as an internal standard, was homogenized in 15 mL chloroform-methanol (2:1，v/v) 
and 3 mL saline. The chloroform-methanol phase was removed and dried down 
under a gentle nitrogen steam. After 1 hour mild hydrolysis with 5 mL NaOH in 
90% ethanol at 90 °C, 1 mL of water and 6 mL of cyclohexane were added for 
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cholesterol extraction. The cyclohexane phase was evaporated to dryness under 
nitrogen, and cholesterol was converted to its TMS-ether derivative by a commercial 
TMS-reagent (dry pyridine-hexamethyldisilazane-trichlorosilane, 9: 3: 1，v/v/v, Sil-A 
regent，Sigma). After 1 hour at 60 °C, the mixture was removed under nitrogen. 
The TMS-ether derivative was dissolved in 600 [i\ of hexane，and after centrifugation, 
the hexane phase was transferred to a vial for gas-liquid chromatograph (GLC) 
analysis. The TMS-ether derivative was analyzed in a fused silica capillary column 
(SAC™-5, 30 m x 0.25 mm, i.d.; Supelco, Inc., Bellefonte, PA, USA) in a Shimadzu 
GC-14B GLC equipped with a flame-ionization detector (Shimadzu). Column 
temperature was set at 285 °C and maintained for 20 minutes. Helium was used as 
carrier gas at a head pressure of 22 psi. A typical GLC chromatogram of liver 
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Figure 3.1 Gas liquid chromatographic profile of cholesterol in the liver 
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3.3.4 Extraction of neutral and acidic sterols from fecal samples 
All the fecal samples were collected at the end of each week. The methods for 
the determination of fecal neutral and acidic sterols were according to Czubayko et al. 
(1991) with some modifications. Fecal samples were first dried in a lyophilizer and 
then grounded into powder form. Stigmasterol (0.5 mg in ImL chloroform) was 
added into a tube as an internal standard for total neutral sterols. The tube was 
dried down under a gentle stream of nitrogen. Then 300 mg of grounded fecal 
sample and 0.5 mg hyodeoxycholic acid (0.5 mg in 2 mL 1 N NaOH) as an internal 
standard for total acidic sterols were added. The samples were then subjected to 
alkaline hydrolysis with 8 mL 1 N NaOH in 90% ethanol at 90 °C for 1 hour 
followed by cooling down to room temperature. Then 1 mL distilled water and 8 
mL cyclohexane were added for extraction. After centrifugation, the upper 
cyclohexane phase and the lower aqueous phase were collected for determination of 
neutral and acidic sterols respectively. 
5.3.4.1 Determination of neutral sterols 
The cyclohexane phase was evaporated to dryness under a gently stream of 
nitrogen. The neutral sterols were converted to their TMS-ether derivatives by 
adding TMS-reagent (dry pyridine-hexamethyldisilazane-trichlorosilane, 9: 3: 1， 
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v/v/v, Sil-A regent, Sigma) and heated at 60 for 1 hour. The mixture was then 
dried down under nitrogen stream and the TMS-derivatives of neutral sterols were 
dissolved in 400 [iL of hexane. After centrifugation, the hexane layer was 
transferred to a vial for G L C analysis. 
3.3.4.2 Determination of acidic sterols 
One m L of 10 N N a O H was added to the lower aqueous phase and the mixture 
was heated for 3 hours at 120 °C. Then 3 m L of distilled water was added to the 
mixture and cooled to room temperature. The mixture was acidified with 1 m L 
25% HCl. And the acidic sterols were extracted with 7 m L diethyl ether for two 
times. The ether phases were pooled together and then dried down under nitrogen 
stream. Methylation of the acidic sterols was performed by adding 2 m L methanol, 
2 m L dimethoxypropane and 40 i^L concentrated HCl. The mixture was mixed 
thoroughly and allowed to stand at room temperature for overnight. The acidic 
sterols were then dried down under nitrogen stream. TMS-reagent was added and 
then heated at 60。C for one hour to convert the acidic sterols into their TMS-ether 
derivatives. The mixture was dried down under nitrogen stream and the TMS-
derivatives of neutral sterols were dissolved in 300 \iL of hexane. After 
centrifiigation, the hexane layer was transferred to a vial for G L C analysis. 
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3.3,4,3 GLC analysis of neutral and acidic sterols 
The analysis of fecal neutral and acidic sterols was carried out in a G L C 
equipped with a fused silica capillary column as described in part 3.3.3. For the 
neutral sterols, the column temperature was set at 285 °C and maintained for 30 min. 
For the acidic sterols, the column temperature was programmed from 230 to 280 °C 
at a rate of 1 °C/ min. Helium was used as a carrier gas at a head pressure of 22 psi 
in both neutral and acidic sterol analysis. Typical chromatograms of neutral and 
acidic sterols were shown in Figures 3.2 and 3.3，respectively. 
3.3.5 Statistics 
Student's t-test and one-way analysis of variance (ANOVA) were used for 
statistical evaluation of differences between groups (SigmaStat version 2.01, 
SigmaStat Advisory Statistical Software, M O , USA) 
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Figure 3.2 Gas liquid chromatographic profile of neutral sterols in feces. 
Identification of peaks: 1，coprostanol; 2, coprostanone; 3, cholesterol; 
4，dihydrocholesterol; 5, campersterol; 6, stigmasterol (internal 
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Figure 3.3 Gas liquid chromatographic profile of acidic sterols in feces. 
Identification of peaks: 1，lithocholic acid; 2, deoxycholic acid; 3， 
chenodeoxcholic acid; 4，cholic acid; 5, hyodeoxycholic acid (internal 
standard) and 6, ursodecholic acid. 
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3.4 Results 
3.4.1 Growth and food intake 
The body weight gain and food intake of hamsters are shown in Table 3.1. 
No significant differences in body weight and food intake were observed among the 
control, SLP and SLEE (Table 3.1). 
3.4.2 Effects of SLP and SLEE supplementation on serum 
triacylglycerol (TG), total cholesterol (TC) and high-density 
lipoprotein cholesterol (HDL-C) 
After hamsters were fed a high-fat and high-cholesterol diet for 4 weeks, their 
serum triacylglycerol, total cholesterol and HDL-C were measured. There were no 
significant differences in serum T G and TC among the three groups (Table 3.2). 
A significant increase in HDL-C by 10.9% was observed in the SLEE group (p< 
0.05) compared with the control group. However, no difference was observed 
between the SLP and control group (Table 3.2). 
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3.4.3 Effects of SLP and SLEE supplementation on non-HDL-C and 
ratio of non-HDL-C to HDL-C 
Non-HDL-C was defined as a difference between TC and HDL-C. Non-HDL-
C levies for the control, SLP and SLEE groups were 87.8 土 5.4，77.3 士 13.9 and 80.1 
士 12.3 mg/dL respectively. A significant reduction of non-HDL-C by 12% and 
8.8% compared with that in the control was observed in the SLP (p< 0.05) and SLEE 
(p< 0.05) groups respectively (Table 3.2). 
When data were expressed as the ratio of non-HDL-C to HDL-C, it was found 
that the SLP and SLEE groups were significantly different from the control (Table 
3.2). 
55 
Table 3.1 Effects of SLP and SLEE supplementations on body weight and food 
intake in hamsters 
Control SLP SLEE 
Initial body wt (g) 132.5 ±5.1 132.7 ±3.9 132.4 ±5.1 
Final body wt (g) 146.3 ±7.6 148.8 ±5.0 149.1 ±8.5 
Liver wt (g) 4.9 ± 0.4 5.0 ±0.4 5.1 ±0.5 
Food intake (g) 6.6 土 0.4 6.4 士 0.8 6.5 土 0.2 
Data are expressed as mean 士 S.D. of n= 12 
SLP: Soy leaves powder group 
SLEE: Soy leaves ethanol extract group 
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Table 3.2 Effects of SLP and SLEE supplementations on serum TG, TC, HDL-C,  
non-HDL-C and the ratio of non-HDL-C to HDL-C  
Control SLP SLEE 
T G (mg/dL) 203.3 ±52.2 200.8 土 47.2 228.8 ±40.3 
TC (mg/dL) 183.6 ±9.3 174.9 ±23.2 184.8 ±11.0 
HDL-C (mg/dL) 95.8 土 7.0a 97.52 ±11.4 104.8 土 10.4' 
Non-HDL-C (mg/dL) 87.83 土 5.4a 773 士 13.9b 80.1 土 12.3' 
Non-HDL-C/ HDL-C 0.92 ± 0.08a 0.79 ±0.11。 0.78 ±0.18。 
Data are expressed as mean 士 S.D. of n= 12 
SLP: Soy leaves powder group 
SLEE: Soy leaves ethanol extract group 
Non-HDL-C = T C - H D L - C 
Means at the same row with different superscripts (a, b) differ significantly (p< 0.05) 
Means at the same row with different superscripts (a, c) differ significantly (p< 0.01) 
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3.4.4 Effects of SLP and SLEE supplementations on concentration 
of hepatic cholesterol 
The liver weights of the hamsters were measured immediately after the 
scarification, no significant differences were found among all the three groups (Table 
3.1). Also, there was no observable difference for the morphology and the color of 
the liver between the control and the treatment groups. The hepatic cholesterol 
contents in the control, SLP and SLEE groups were 24.9 ±4.1, 30.4 土 4.2 and 30.3 土 
2.8 mg/ g of liver respectively. It was found that the hepatic cholesterol contents in 
SLP (p< 0.01) and SLEE (p< 0.01) groups were significantly higher than the control 
group (Figure 3.4). 
3.4.5 Effects of SLP and SLEE supplementations on perirenal 
adipose tissue cholesterol 
There was no significant difference in perirenal adipose tissue cholesterol 
content among the three groups (Figure 3.5). 
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Figure 3.4 Effects of soy leaves powder (SLP) and soy leaves ethanol extract 
(SLEE) on concentration of hepatic cholesterol in hamsters. Data are 
expressed as means 土 S.D. of n= 12. Means with different superscript 
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Figure 3.5 Effects of soy leaves powder (SLP) and soy leaves ethanol extract 
(SLEE) on perirenal adipose tissue cholesterol. Data are expressed as 
mean 土 S.D. of n= 12 
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3.4.6 Effects of SLP and SLEE supplementations on fecal neutral 
and acidic sterols 
The neutral sterols refer to the sum of coprostanol, coprostanone, cholesterol, 
dihydrocholesterol, campersterol, and p-sitosterol. The total fecal neutral sterols 
were significantly elevated in the SLP group compared with that in the control. 
Supplementation of SLEE in the diet slightly increased the excretion of total neutral 
sterols but no statistical differences were observed between the SLEE hamster and 
the control group (Figure 3.6). 
The acidic sterols measured include lithocholic, deoxycholic, cholic and 
ursodeoxycholic acid. Supplementation of SLP and SLEE did not affect the fecal 
excretion of acidic sterols as compared with the control except at week 2 when 
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Figure 3.6 Effects of SLP and SLEE supplementations on concentration of fecal 
neutral sterols. Data are expressed as mean 士 S.D. of n= 4 cages. 
Means with different superscript letter (a, b) differ significantly at p< 
0.05. SLP: Soy leaves powder group; SLEE: Soy leaves ethanol 
extract group. 
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Figure 3.7 Effects of SLP and SLEE supplementations on the concentration of 
fecal acidic sterols. Data are expressed as mean 土 S.D. of n= 4 cages. 
Means with different superscript letter (a, b) differ significantly at p< 




The present study demonstrated that supplementation of soy leaves in the diet 
could not decrease serum total T G and TC. However, there was a significant 
decrease in the ratio of non-HDL-C to HDL-C in the SLP and SLEE groups, 
suggesting that supplementation of SLP and SLEE could cause the redistribution of 
serum cholesterol. This ratio is commonly used as a risk factor in cardiovascular 
disease. The higher the ratio, the greater the chance of getting cardiovascular 
diseases. If the data could apply to humans, the decrease in the ratio of non-HDL-C 
to HDL-C indicated that soy leaves supplementation in the diet might be associated 
with a decreased risk of cardiovascular diseases. 
The effect of SLP and SLEE on serum lipoprotein profile may not be ftilly due 
to the effect of dietary fiber. First, both SLP and SLEE groups had a significantly 
lower ratio of non-HDL-C to HDL-C compared with the control. However, only 
SLP diet contained fiber while SLEE did not had any fiber. Second, the effect of 
dietary fiber on serum cholesterol is different from the observation in the present 
study. From a meta-analysis of the cholesterol-lowering effects of dietary fiber, 
Brown et al (1999) reviewed that dietary fiber can generally decrease the total serum 
cholesterol with the HDL-C being unaffected. 
Previous studies showed that supplementation of soy-protein could significantly 
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increased the HDL-C and decreased the ratio of LDL-C to HDL-C, but total serum 
cholesterol was not significantly reduced in humans (Nilausen and Meinertz 1998). 
This is in agreement with the result in the present study, implying that some of the 
common components present in soy leaves and soybean might be responsible for 
hypolipidemic activity of soy products. A previous study showed that 
supplementation of soy isoflavones in the diet could decrease non-HDL-C and 
increase HDL-C (Anthony et al 1998). Since, genistein can bind to estrogen 
receptors (Kuiper et al. 1998) to exert estrogenic activity and may share the LDL 
reducing and H D L increasing effect of human estrogen (Lilley et al. 1998; 
Westerveld 1998; Godsland 2001). Therefore, soy isoflavones may be one of the 
active ingredients which were responsible for the observed effect. 
The mechanisms by which SLP and SLEE lowered the ratio of non-HDL-C to 
HDL-C remained unexplored. One of the possible mechanisms may be associated 
with increased fecal excretion of neutral and acidic sterols. Another possibility is 
that supplementation of SLP and SLEE increased the catabolism of cholesterol in the 
liver. The present results showed that there was an increase in the hepatic 
cholesterol in the SLP and SLEE groups. This might be due to the increase in 
serum HDL-C that increased the rate of cholesterol transported from the peripheral 
parts of the body back to the liver for degradation. However, the rate of cholesterol 
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metabolized by the liver to form the acidic sterols might not as high as the rate of 




Effects of soy leaves and its flavonoid glycosides 
on haemolysis and on LDL oxidation 
4.1 Introduction 
In recent years, there has been a great interest in health effects of dietary 
antioxidants against coronary heart disease (Parthasarathy et al. 1998). The 
underlying cause of coronary heart disease, strokes and peripheral arterial disease is 
mainly atherosclerosis. It is responsible for about half the deaths in the developed 
countries and its incidence in developing countries is increasing. 
The major harmful effect of atherosclerosis is on the large and medium-sized 
arteries. The arterial wall has three layers namely innermost layer, tunica intima, 
tunica media and tunica adventitia. The intima is normally a thin layer but becomes 
greatly thickened when an atherosclerotic lesion forms. The formation of 
atherosclerotic lesions may last over a period of years or decades, but their bulk can 
impede the flow of blood through the arteries. Most heart attacks (myocardial 
infarctions) are due to the sudden fissuring of an atherosclerotic lesion. These 
fissures cause blood to come into contact with substances inside the lesions that 
cause a thrombus and block the flow of blood (Wilcox et al 1995), leading to a 
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myocardial infarction if the artery supplies the muscles of the heart. 
4.1.1 Role of low density lipoprotein oxidation in the 
development of atherosclerosis 
The oxidative theory of atherosclerosis proposes that it is not LDL itself but 
oxidized L D L that is atherogenic in the arterial wall (Diaz et al. 1997 and Young et 
al. 2001). LDL enters the arterial wall from the plasma and accumulates in the 
extracellular subendothelial space of arteries and, through the action of resident 
vascular cells, is mildly oxidized to a form known as minimally modified LDL. 
This minimally modified LDL induces local vascular cells to produce monocyte 
chemotatic protein, which stimulates monocyte recruitment and differentiation to 
macrophages in arterial walls (Parhami et al 1993). The accumulating monocytes 
and macrophages stimulate further peroxidation of LDL. 
In contrast to the uptake of native LDL by the L D L receptor on macrophages, 
the uptake of oxidized L D L by the scavenger-receptor pathway is not subject to 
negative-feedback regulation. The aldehydes formed during L D L oxidation can 
combine with the epsilon-amino groups of the lysyl residues of apo B-lOO to form 
Schiff bases. When a Schiff base forms, the normal positive charge of the lysyl 
residue is abolished and the LDL particles acquire a greater negative charge 
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(Steinbrecher 1987). As a result, the oxidized LDL can no longer be recognized by 
the native LDL receptor and thus results in massive uptake of cholesterol (from 
oxidized LDL) by the macrophages (Diaz et al 1997). The amount of cholesterol 
in LDL entering the cells thought to overwhelm the capacity of the macrophages to 
release it and the cholesterol therefore accumulate inside the cells, converting them 
into foam cells Figure 4.1. Oxidized LDL also has direct chemotactic activity for 
monocytes and stimulates the binding of monocytes to the endothelium. The 
monocytes will become trapped in the subendothelial space, if they cross the 
endothelial layer. This is because that oxidized LDL can inhibit their egress from 
the arterial wall (Quinn et al 1987). 
In the later lesions, deposition of extracellular cholesterol esters forms a large 
pool of lipids at the base of the lesions. Then proliferation of smooth muscle cells 
in the intima will occur and these smooth muscle cells will secrete large amounts of 
collagen, which adds bulk to the lesions. The macrophages die in the deeper parts 
of the lesions, mainly at the edge of the lipid pool in advanced lesions. Therefore, 
oxidation of L D L is highly related to atherosclerosis. 
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4.1.2 LDL oxidation 
LDL is subject to oxidation in many cell types, including monocytes, 
macrophages, neutrophils, endothelial cells, smooth muscle cells and fibroblasts. 
However, the cell types that are mainly responsible for the oxidation of LDL and 
atherosclerosis are macrophages, endothelial cells and smooth muscle cells (Yong et 
al 2001). The mechanisms by which these cells oxidize LDL are poorly 
understood. Involvement of superoxide (Steinbrecher et al 1988 and Hiramatsu et 
al 1987) and lipoxygenase (Parthasarathy et al 1989 and Rankin et al 1991) have 
been proposed. Another proposed mechanism was that cells might oxidize LDL by 
releasing the thiol-containing amino acid cysteine (Heinecke 1987). Oxidation of 
cysteine led to form cystine in the extracellular space, producing sulf- or oxygen 
centered free radicals that may attack LDL. When cysteine is oxidized to cystine, 
iron (III) may be reduced to iron (II) while copper (II) is converted to copper (I). 
These transition metal ions in their valency states may oxidize L D L better than in 
their higher valency states (Heinicke et al 1987). 
Whatever the mechanism is, oxidation of LDL will involve the abstraction by an 
unidentified free radical of a hydrogen atom from a methylene (CHj) group of a 
polyunsaturated fatty acid (PUFA). Molecular rearrangement of the resulting 
unstable carbon radical results in a more stable configuration, a conjugated diene. 
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The conjugated diene reacts very quickly with molecular oxygen, and the peroxyl 
radical thus formed a crucial intermediate. The PUFA peroxyl radical in LDL may 
abstract a hydrogen atom from an adjacent PUFA to form a hydroperoxide and 
another lipid radical, a reaction which results in chain propagation. The fragments 
of lipid hydroperoxides will eventually break down into shorter-chain aldehydes and 
other products, including malondialdehyde (MDA) and 4-hydroxynonenal (Figure 
4.2) (Young etal 2001) 
4.1.3 Thiobarbituric acid reactive substances (TEARS) as an index 
of LDL oxidation 
Measurement of TBARS formation is a most frequently used test as an index of 
lipid peroxidation. The breakdown product of lipid peroxidation, malondialdehyde 
(MDA), is formed when lipid hydroperoxide is decomposed during L D L oxidation 
(Figure 4.2). These M D A molecules react with thiobarituric acid (TBA) in acidic 
condition to form a pink chromagen, which has an absorption maximum at 532 nm. 
The amount of these chromagen can be quantified by spectrophotometrically or 
fluorometrically (Ohkawa et al 1978). This method is sensitive to determine the 
degree of lipid peroxidation. 
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Oxidative Modifications of LDL and Atherosclerosis 
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Figure 4.1 Macrophage-mediated oxidation and aggregation of LDL, formation of 
foam cells (Adapted from Aviram et al 1998) 
Native LDL particles migrated into the extracellular subendothelial space and 
then oxidized by the adjacent cells. The oxidized LDL was taken up by the 
macrophages. Cholesterol esters in oxidized L D L enter the macrophages and 
overwhelm their capacity to release them. These cholesterol esters therefore 
accumulate inside the cells, converting them into foam cells. 
CE: Cholesterol ester 
SMC: Smooth muscle cell 
Ox-LDL: Oxidized LDL 
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Figure 4.2 Basic reaction sequence of lipid peroxidation (Adapted from Young 2001 
with some modifications) 
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4.1.4 Antioxidant and LDL oxidation 
The major lipid-soluble antioxidant present in LDL is vitamin E (a-tocopherol). 
Enrichment of vitamin E has been shown to retard LDL oxidation and inhibit the 
proliferation of smooth muscle cells (Chan 1998). 
Some natural antioxidants, for example, flavonoids may protect vitamin E in 
LDL, either by scavenging free radicals themselves or by regenerating vitamin E 
from its radical form (Zhu et al 1999). Some studies showed that a mixture of 
flavonoid, a-tocopherol and ascorbic acid might inhibit LDL oxidation 
synergistically (Negre et al 1995 and Hwang et al 2000). 
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4.2 Objective 
The objective of the present study was to examine the antioxidative effects of 
three different soy leaves extracts and their flavonoid glycosides by using Cu^ -^
mediated human LDL oxidation and inhibition on haemolysis as two different assay 
models. The possible mechanism of their antioxidative effects was also determined. 
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4.3 Materials and methods 
4.3.1 Isolation of LDL from human serum 
Fresh human serum was collected from healthy subjects at the Prince of Wales 
Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. To prevent 
lipoprotein modification, E D T A and NaN^ were added to the serum collected (final 
concentrations of E D T A and NaN^ were 0.1% and 0.05%, respectively). L D L was 
isolated from the serum according to the method described previously (Havel et al. 
1995). In order to prevent L D L from oxidation, the centrifuge tubes containing 
serum were flushed with nitrogen gas. Firstly, the serum was centrifuged at 1500 g 
for 15 minutes to remove cells and cell debris. NaCl-KBr solution (dissolve 153 g 
NaCl，354 g KBr and 100 |ag E D T A in one liter of water, 1.33 g/mL) was then added 
to increase the density to 1.019. The serum was re-centrifuged at 160,000 g for 20 
hours at 4 After the removal of the top layer containing chylomicron and very 
low-density lipoprotein (VLDL), the density of remaining serum fractions was 
increased to 1.064 and re-centrifuged at 160,000 g for an additional 24 hours at 4 °C. 
The top L D L fraction was collected and then flushed with nitrogen and stored at -70 
°C. The protein content of isolated L D L was determined using Lowry's method 
(Lowry et al. 1951). 
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4.3.2 LDL oxidation 
The stock LDL fraction (5 mg protein/mL) was dialyzed against 100 volumes of 
the degassed dialysis solution (pH = 7.4) containing 0.01 M sodium phosphate, 0.9 
% NaCl, 10 ^ M EDTA and 0.05% NaN] in dark at 4。C for 24 hours. The dialysis 
solution was changed four times. Oxidation of LDL was conducted as previously 
described by Puhl et al. (1994). LDL protein (100 |ig) was incubated in a mixture 
containing 5 j^M CuSO^ at 37 °C for up to 24 hours. The oxidation of LDL was 
then stopped by addition of 25 |iL 1.0% EDTA and cooled at 4 °C. 
4.3.3 Determine the formation of thiobarbituric acid-reactive 
substances (TEARS) 
The degree of LDL oxidation was monitored by measuring the production of 
T B A R S as previously described (Buege & Aust 1978). After the reaction was 
stopped by addition of EDTA at 4 °C, 2 m L of 0.67% thiobarbituric acid and 15% 
trichloroacetic acid in 0.1 N HCl solution were added to the LDL-incubated tube. 
The incubation mixture was then heated at 95 °C for 1 hour, cooled on ice, and 
centrifuged at 1000 g for 20 minutes. The formation of T B A R S was determined by 
measuring the absorbance at 532 nm. Calibration was done with a malondialdehyde 
(MDA) standard solution prepared from tetramethoxylpropane. The extent of LDL 
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oxidation was expressed as nmol MDA/mg LDL protein. 
4.3.4 Assay for erythrocyte haemolysis 
The erythrocyte hemolysis assay was performed according to the procedures 
described by Ng et al (2000) with some modifications. 
Fresh rabbit blood was collected from the New Zealand white rabbits and kept 
at 4 °C before use. Erythrocytes were separated by centrifugation at 1500 g for 20 
minutes at 4 °C. The erythrocytes were then washed three times with 10 volumes of 
lOmM phosphate buffered saline (PBS) which was prepared by mixing, 2.88 g 
Na2HP04.2H20, 0.488 g,題2?04 and 18 g NaCl in 2000 m L 即 at pH 7.4. 
During the last washing, the erythrocytes were centrifuged at 1500 g for 10 minutes 
to obtain a constantly packed cell preparation. The packed erythrocytes were 
diluted to 20% of the original concentration by using PBS. One milliliter of 200 
m M 2, 2'-azo-bis (2-amidinopropane) dihydrochloride (AAPH) (Wako, Japan) in 
PBS, 0.5 m L test substance or 0.5 m L PBS as control and 1 m L erythrocytes 
suspension were mixed and incubated at 37 for 2.5 hr. After incubation, 4 m L 
PBS was added into the reaction mixture. The diluted mixture was centrifuged at 
1000 g for 10 min. Absorbance (A) of the supernatant was measured at 540 nm. 
P e r c e n t a g e inhibition of haemolysis was calculated by the equation: % i n h i b i t i o n : 
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(1 - Ates/ Acontroi) X 100%. Epigallocatcchin gallate (EGCG) was used as a positive 
control. 
4.3.5 Statistics 
Results were expressed as mean 土 standard deviation (S.D.). Student's t-test 
and one-way analysis of variance (ANOVA) were used for statistical evaluation of 
differences between groups (SigmaStat version 2.01, SigmaStat Advisory Statistical 
Software, M O , USA) 
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4.4 Results 
4.4.1 Effects of three different soy leaves extracts and flavonoid 
glycosides on LDL oxidation 
LDL was oxidized significantly within 2 hours in the control. Six different 
kaempferol glycosides at a concentration of 40 |aM showed no or very little 
protection to LDL from Cu2+ -mediated oxidation (Figure 4.3). LDL was oxidized 
completely within 4，6 and 8 hours in the presence of 0.1 mg/mL soy leaves water, 
chloroform and butanol extracts respectively (Figure 4.4). L D L was also oxidized 
completely within 4 hours in the presence of 40 ^iM genistein (Figure 4.4). On 
the other hand, the positive control LDL in the presence of 40 |iM EGCG, a major 
antioxidant present in green tea, did not show any oxidation throughout the period of 
24 hours incubation (Figure 4.4). 
4.4.2 Effects of three soy leaves extracts and flavonoid glycosides on 
erythrocyte haemolysis 
The water and chloroform extracts showed a very little inhibition on erythrocyte 
haemolysis at the concentration of 0.1 mg/mL (< 5%). The butanol extract, 
showed 10.7% and 37.0% inhibition on erythrocyte haemolysis at the concentrations 
of 0.05 and 0.1 mg/mL respectively. The pure kaempferol glycosides at the 
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concentration of 20 |liM and 40 [iM exhibited inhibitor! on erythrocyte haemolysis by 
> 20% and > 60% respectively. In contrast, inhibition of E G C G at 20|iM and 
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Figure 4.3 Inhibitory effects of six different kaempferol glycosides from soy 
leaves on the production of thiobarbituric acid reactive substances (TBARS) in Cu^^-
mediated oxidation of human LDL. Data are expressed as mean 土 S.D. of n= 3. 
Means at the same time point with different letters (a- b) differ significantly from the 
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Figure 4.4 Inhibitory effects of three different soy leaves extracts on the 
production of thiobarbituric acid reactive substances (TEARS) in Cu2+-mediated 
oxidation of human LDL. Data are expressed as mean 土 S.D. of n= 3. Means at 
the same time point with different letters (a- f) differ significantly from the control 
values (p<0.01) 
E G C G : Epigallocatechin gallate 
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Table 4.1 Inhibitory effects of three different soy leaves extract and six different 
kaempferol glycosides from soy leaves on erythrocyte haemolysis. 
% inhibition 
Control (PBS) q.O ± 0.2' 
20)liM kaempferol-3-O-a-L-rhamnopyranosyl (1 •>2 ) -P -D- 23.5 ± 0 .4 ' 
glucopyranosyl (1 ^ 6)-P-D-galactopyranoside  
20|iiM kaempferol-3-0-(2,6-di-0-a-rhamnopyranosyl)-P- 22.2 ± 0.4' 
galactopyranoside  
20|liM kaempferol-3-O-digalactopyranoside 22.6 ± 0.5' 
20 |LiM kaempferol-3-O-diglucopyranoside 24.3 土 0.6。 
20|^M kaempferol-3-O-a-L-rharmnopyranosyl (1^6)- p-D- 20.4 土 0.5。 
galactopyranoside  
20|LiM kaempferol-3-O-rutinoside 23.8 ± 0.4' 
E G C G ( 2 0 _ 3 8 : 5 ; 0 : 9 E — 
40|liM kaempferol-3-O-a-L-rhamnopyranosyl (1 今2 ) - P - D - 60 .8 ± 0 .3 ' 
glucopyranosyl (1 ->6)-(3-D-galactopyranoside  
40|iM kaempferol-3-0-(2,6-di-0-a-rhamnopyranosyl)-P- 68.4 ± 1.9' 
galactopyranoside  
40|iM kaempferol-3-O-digalactopyranoside 60.0 ± 0.7' 
4 0 | I M kaempferol-3-O-diglucopyranoside 69 .8 ± 0 .6 ' 
40|iM kaempferol-3-O-a-L-rhannnopyranosyl (1 ->6)- (3-0- 62.2 ± 0.6' 
galactopyranoside  
40|iM kaempferol-3-O-rutinoside 69 2 ± 1 
E G C G ( 4 0 _ 8 2 : 7 : 1 : 6 � — 
Butanol extract (0.05mg/mL) 10 7 ± 0 7' 
Water extract (0.05mg/mL) j j + q g 
Chloroform extract (0.05mg/mL) [7 ± o 
Butanol extract (O.lmg/mL) 37 q + j jc 
Water extract (O.lmg/mL) s Y + T ^ 
Chloroform extract (0.1 mg/mL) 4 g + q ^c 
Data are expressed as mean 土 S.D. of n= 3. 
Means at the same row with different superscripts (a, b) differ significantly (p< 0.05) 
Means at the same row with different superscripts (a, c) differ significantly (p< 0.01) 
EGCG: Epigallocatcchin gallate 
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4.5 Discussion 
Oxidative stress in the body can damage to macro-molecules like D N A , proteins 
and lipids, and might be involved in atherosclerosis (Holvoet et al 1998 and 
Heinecke 1998), cancer (Keum et al 2000; Mukhtar et al 2000 and Steele et al. 
2000) and chronic inflammation (Halliwell 1994). In atherosclerosis, for example, 
oxidation of low density lipoproteins is thought to play an important role (Hamilton 
1997 and Young et al 2001). It has been hypothesised that the flavonoid 
antioxidants may protect tissue against damage caused by free radicals (Aviram et al 
1998). 
The present study demonstrated that kaempferol glycosides from soy leaves did 
not show any antioxidative effect on Cu^ -^ mediated LDL oxidation. But soy leaves 
butanol, water and chloroform extracts showed a weak antioxidative effect on LDL 
oxidation. This indicated that the antioxidant present in these soy leaves extracts 
were not due to kaempferol glycosides. At the concentration of 0.1 mg/mL soy 
leaves butanol extract, the total concentration of genitein and its glycosides was 4.0 
|iM (Table 4.2). It was assumed that genistein and its glycosides at this 
concentration could not protect LDL from Cu】、mediated oxidation. Since 
genistein at the concentration of 40 |aM, LDL was oxidized significantly within 4 
hours. This proved that the antioxidative effect of soy leaves butanol extract was 
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not due to genistein and its glycosides. The present results indicated that the major 
antioxidant present in soy leaves butanol extract which was responsible for 
protecting LDL from Cu^ ""- mediated oxidation has not been isolated. 
Vitamin E (a- tocopherol) is a major lipid soluble antioxidant present in LDL 
(Anitra et al. 2000). Depletion of endogenous vitamin E would lead to LDL 
oxidation (Diaz et al 1997). Regeneration of vitamin E by the secondary 
antioxidant can inhibit LDL oxidation and decrease the rate of atherosclerosis (Chan 
2000 and Hamilton 1997). Jovanovic et al. (1998) showed the reduction poteintial 
of vitamin E was 0.48 V. Some flavonoids, epigallocatechin (0.42 V)， 
epigallocatechin gallate (0.43 V) and querectin (0.33 V) (Jovanovic et al. 1998), their 
reduction potentials were smaller than viatmin E (0.48 V)，therefore, they may repair 
vitamin E radical and maintaining desirable concentration of this important 
physiological antioxidant (Zhu et al 1999 and Zhu et al. 2000). However, the 
reduction potential of kaempferol was found to be 0.75 V (Jovanovic et al. 1997) 
which was greater than vitamin E (0.48 V). Therefore, kaemfperol could not 
regenerate vitamin E and is unable to protect LDL from oxidation through this 
mechanism. 
86 
Haemolysis assay showed that kaempferol glycosides from soy leaves could 
significantly inhibit erythrocyte haemolysis in a dose-dependent manner. This may 
be due to the effect of flavonoids on the inactivation of superoxide radical and singlet 
oxygen generated by AAPH. Jovanovic et al. (1997 and 1998) showed the 
reactivities of flavonoids and gallocatechins with the superoxide radical were 
expected from their excellent electron donating abilities, even the poorest electron 
donor, galangin, with the inactivation rate constant of k= 8.8 x 10^ M"' S] (Jovanovic 
et al 1994), still efficiently scavenged superoxide radical (Jovanovic et al 1998). 
In this regard, kaempferol and its glycosides are probably efficient scavengers of 
singlet oxygen and proxyl free radicals as shown in the present study. Although the 
six major kaempferol glycosides present in soy leaves could not protect LDL from 
Cu2+-mediated oxidation, they may protect various biomolecules from oxidation and 
prevent cell death and mutations (Sloley et al, 2000 and Asgary et al 1999). Other 
components in soy leaves may also be beneficial to humans including genistein and 
its glycosides on cardiovascular system and on cancer prevention (Lichtenstein 1998; 
Kerry et al 1998; Arorra et al 1998 and Lamartiniere 2000). 
The experimental results in this study suggest that the major antioxidant present 
in soy leaves has not been isolated. Further studies should be carried out to isolate 
unknown antioxidant(s). 
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Table 4.2 Composition of the flavonoids and their glycosides present in soy leaves 
butanol extract. 
Flavonoids (mg/g) 
Kaempferol-3-O-a-L-rhamnopyranosyl (l->2)-p-D- 52.0 士 11 
glucopyranosyl (1 ->6)-(3-D-galactopyranoside  
Kaempferol-3-0-(2,6-di-0-a-rhamnopyranosyl)-P- 130 ±2.6 
galactopyranoside  
Kaempferol-3-O-digalactopyranoside 56.2 ± 0.4 
Kaempferol-3-O-diglucopyranoside 43.5 ± 0.3 
Kaempferol-3-O-a-L-rharmnopyranosyl (1^6)- p-D- 81.5 ±0.6 
galactopyranoside  
Kaempferol-3-O-rutinoside 104.4 ± 1.2 
“stin 6.7 土 0.1 
Malonyl-genistin 12.6 ± 0.1 
Genistein 0.0 土 0.0 
Data are expressed as mean 土 S.D. of n= 3 
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Chapter 5 
Relaxing effects of soy leaves and its flavonoids 
5.1 Introduction 
An increased total peripheral resistance is a universal characteristic of 
hypertension. The increase in the total peripheral resistance is usually due to the 
hypertensive contraction of the smooth muscles in the blood vessels. Hypertension 
is dangerous for a number of reasons. First, high arterial pressure makes the 
ventricles more difficult to eject blood. As a result, the heart must work harder, 
which can result in pathological changes in heart structure and function, leading to 
congestive heart failure. Additionally, hypertension increases the risk of heart 
attack and produces damage to the kidneys, nervous system, and especially the eyes. 
High pressure may damage cerebral blood vessels, leading to cerebrovascular stroke. 
Finally，hypertension contributes to the development of atherosclerosis. This may 
due to the adaptive response to prolonged high blood pressure making the arterial 
wall becomes thickened. 
Vasodilators are the agents that can directly act on the smooth muscle cells and 
decrease the contractile responses of the smooth muscles in the blood vessels. 
These vasodilators can either decrease the elevated contractile tone or preventing the 
increase in contractile response. Since the leading causes of vascular hypertension 
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are not changed by vasodilators, therefore, vasodilators do not cure hypertension. 
However, the effect of dilating or preventing constriction of resistance vessels by 
vasodilators can decrease elevated blood pressure or block the onset of increased 
vascular tone. As a result, the harmful effects caused by hypertension can be 
decreased. 
5.1.1 Smooth muscle contraction 
Smooth muscles are arranged in circular layers around the walls of blood 
vessles. They contain a great deal of actin and some myosin, which produce a ratio 
of thin-to-thick filaments of about 16:1. The contraction of smooth muscles is 
triggered by the increase in Ca^^ concentration within the cytoplasm of the smooth 
muscle cells. Extracellular Ca^^ influx into the smooth muscle cell is primarily 
through voltage-sensitive Ca^^ channels in the cell membrane. The opening of these 
Ca2+channels is graded by the amount of depolarization. 
In smooth muscles, Ca〗. combines with a protein in the cytoplasm called 
calmodulin. The calmodulin- Ca^^ complex thus formed combines with and 
activates an enzyme called myosin light chain kinase, which catalyzes the 
phosphorylation of the myosin cross bridges (Walsh et al. 1995). The cross bridges 
must be phosphorylated before they can bind to actin. The concentration of Ca^^ in 
90 
the smooth muscle cell cytoplasm determines how many cross bridges will combine 
with actin, and thus determines the strength of contraction. The contraction of 
smooth muscle is believed through a sliding filament mechanism similar to that in 
striated muscle. 
5.1.1.1 Sliding filament mechanism 
This mechanism is involved in both actin (thin filament) and myosin (thick 
filament) in smooth muscle cells. The actin filament consists of 300 to 400 
contractile protein, G-actin monomers, which are arranged in a double row and 
twisted to form a helix. The myosin filament of smooth muscle is comprised 
entirely of the contractile protein, myosin. Myosin is a hexameric molecule 
consisting of two high molecular weight subunits (heavy chain) and four low 
molecular weight subunits (light chain). The overall configuration is that of an 
intertwined coiled tail region with two protruding "cross bridge" and “myosin head" 
regions. Each myosin head contains an ATP-binding site closely associated with an 
actin-binding site (Smith et al. 1987). The myosin head functions as myosin 
ATPase, splitting ATP into A D P and Pj. This reaction occurs before the myosin 
head combines with the actin, and indeed is required for activating the myosin head 
to attach to the actin. When the myosin head binds to the actin, it undergoes a 
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conformational change that the A D P and Pj are released and the cross bridge changes 
their orientation, resulting in a power stroke. This power stroke pulls the actin 
filaments and causes the actin and myosin filaments to move past one another 
(Figure 5.1). 
5.1.2 Intracellular mechanisms involved in the regulation of smooth 
muscle contraction 
5.1,2.1 Voltage-gated Ca^^ channels 
Voltage-gated calcium channels are sensitive to changes in the electrical 
potential across the cell membrane. Upon depolarization, these channels change 
from resting to activated states within milliseconds and then inactive rapidly. 
Repolarization is necessary to return to the resting state again (Hockerman et al 
1997). The entry of Ca2+ into cells through voltage-gated channels is coupled to 
many cellular responses, such as neurosecretion and muscle contraction. Several 
types of voltage-gated Ca^ "" channels have been identified and have been designated 
L，N, P, Q, R, and T. In smooth muscle, only the L-type Ca^^ channel is considered 
to be a major Ca^^ influx pathway (Ganitkevich and Isenberg 1991; Vogalis et al. 
1991; Kuriyama et «/.,1995; Knot et al. 1996; Hockerman et al 1997). The L-type 
Ca2+ channel with a high sensitivity to several classes of drugs that have been used as 
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selective L-type Ca^^ channel blockers. The three main classes of L-type-selective 
Ca2+ channel blockers currently available for clinical use are the phenylalkylamines, 
the benz(othi)azepines, and the dihydropyridines. These drugs bind to three 
separate receptor sites on L-type Ca^^ channels, which are allosterically linked 
(Gould et al 1983; Glossman et al. 1984; Hockerman et al. 1997). 
High K+-induced depolarization induces a sustained increase in cystolic Ca^^, 
due to the opening of the voltage-dependent Ca^^ channels, and a sustained 
contraction. 
5.1,2,2 Protein kinase C (PKC) mediated smooth muscle contraction 
One common denominator in signal transductions involved adenylate cyclase, a 
transmembrane receptor-tyrosine kinase, phospholipase C, or an ion channel is the 
eventual regulation of the activity of a protein kinase. Protein kinase can 
phosphorylate serine or threonine residues of specific target proteins, changing their 
catalytic activities. 
Protein kinase C is one of the protein kinases that is believed to be involved in 
the regulation of diverse cellular process such as growth, differentiation, metabolism, 
secretion and smooth muscle contraction. 
Five isoenzymes of P K C (a, p, 5，s and ;) have been detected in vascular 
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smooth muscles, but not all of these appear to be expressed in all vascular smooth 
muscle tissue (Danthuluri. and Deth 1984; Morgrga and Morgan 1984; Khalil et al 
1992; Kanashiro and Khalil 1998). 
A possible substrate of P K C in the smooth muscle is a specific, and thin 
filament associated protein, calponin. Calponin is phosphorylated in intact smooth 
muscle strips in response to carbachol, endothelin-I, phorbol esters, or okadaic acid. 
Phosphorylation of calponin in vitro by P K C dramatically reduces its affinity for F-
actin and alleviates its inhibition of the cross-bridge cycling rate. As a result, it can 
cause the contraction of smooth muscle (Walsh et al 1996). 
Kanashiro and Khalil (1998) suggest that eicosanoid-induced contraction is 
associated with significant P K C activity that is dependent on Ca^^ entry and may 
involve activation and translocation of the Ca^^-dependent a-PKC isoform. Three 
subclasses of eicosanoid are postaglandins, leukotrienes and thromobaxanes. 
5. L2.3 Thromboxane A! receptor-mediated calcium channel 
Thromboxane A : (TXA�）is formed from its precursor, arachidonic acid. It 
has a six-membered ring containing an ether. It possesses a high affinity for the 
TXA2 receptor mediated Ca^^channel and produces the Ca^^ influx (Tosun et al. 
1997). The influx of Ca2+can cause smooth muscle contraction. 
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The objective of the present study was to examined the effects of soy leaves and 
its flavonoids on the contractile response to various agonists in rat isolated carotid 
artery rings. 
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5.3 Materials and methods 
5.3.1 Drugs preparation 
The following drugs used include phenylephrine hydrochloride, acetylcholine 
hydrochloride, 9,11 -dideoxy-11 „,9„-epoxy-methanoprostaglandin Fj^ (U46619)， 
[5Z,9„, 1 1 3 E , 15S]-9,11,15-trihydroxyprosta-5,13-dienoic acid (PGF2J, phorbol 12-
myristate 13-acetate (PMA), glibenclamide, nifedipine, staurosporine, paraverine and 
kaempferol (Sigma, St. Louis, M O , USA). Soy leaves butanol extract and 
kaempferol glycosides were purified as described in Chapter 2 part 2,3,1.1 and 
23,1.2, Glibenclamide, P M A , staurosporine and nifedipine were dissolved in 
dimethyl sulfoxide (DMSO) and others in distilled water. D M S O at 0.2-0.6% (v/v) 
did not affect the sustained contraction induced by U46619. 
5.3.2 Vessel preparation 
After the approval from Animal Ethical Committee of Chinese University of Hong 
Kong was obtained, male Sprague-Dawley rats (250-300 g) were killed by cervical 
dislocation. The common carotid artery from both sides was dissected free from 
surrounding tissues and cut into rings of 3 m m in length. The preparation was then 
transferred into 10 ml organ baths containing Krebs solution bubbled with a mixture of 
95% O2 plus 5 % CO2. Each ring was mounted between two L-shaped stainless steel 
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hooks. One hook was mounted at the bottom of the bath while the other was 
connected to FT03 force-displacement transducer (Grass Instruments Co). Krebs 
solution contained (mM): 119 NaCl, 4.7 KCl, 2.5 CaClj, 1 MgCl� �25 N a H O V .〗 
KH2PO4, 11 d-glucose. A passive tone of 5 m N was applied to all artery rings. All 
experiments were performed at 37 In some arterial rings, the endothelial layer was 
mechanically removed by gently rubbing the luminal surface of the artery back and 
forth several times with plastic tubing. The tissues were allowed to equilibrate for 90 
minutes, during which the bath solution was replaced with pre-warmed and 
oxygenated Krebs solution every 15 minutes. Endothelium integrity or functional 
removal was verified by the presence or absence, respectively, of the relaxant response 
to 1 |xM acetylcholine under the contraction induced by lO^iM phenylephrine at the 
start of each experiment. Then the rings were rinsed with pre-warmed and 
oxygenated Krebs solution several times until the basal level of tension was restored. 
The rings were allowed to equilibrate for additional 60 minutes. Each experiment 
was performed on the rings prepared from different rats. 
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5.3.3 Contraction experiments 
5.5.5.7 Relaxant responses of soy leaves butanol extract on the contraction 
induced by different constrictors 
In the first set of experiments, a sustained vessel tone was induced by three 
constrictors, 30 NM U46619, 10 |liM phenylephrine and 50 m M external K+，soy leaves 
butanol extract was added cumulatively to the bathing solution. These experiments 
were also repeated in the endothelium-denuded artery rings to examine the possible 
involvement of endothelium in extract-induced relaxant response. The effect of 
extract was also tested on the contractile response to 1 ^ iM P M A in Ca^ -^free Krebs 
solution containing 0.5 m M Noj-EGTA. In control experiments, Glibenclamide (an 
antagonist of prostaglandins) was used to inhibit U46619-induced contraction; 
nifedipine (L-type voltage-gated Ca^^ channel blocker) used to inhibit the high K+ 
response; and staurosporine (a protein kinase C inhibitor) used to inhibit PMA-induced 
contraction. 
In the experiments using high K+ solution, Na+ was replaced with an equimolar 
amount of K+ to maintain the ionic strength. 
5,3,3.2 Relaxant responses of soy leaves butanol extract on U46619 and PGF2a-
induced contraction 
99 
In the second series of experiments, the endothelium-intact ring was contracted by 
U46619 (0.03-300 nM) or PGFj^ (0.03- 3 ^iM) to construct the first concentration-
contraction curve. Once the maximum contraction was obtained, the ring was washed 
off the constrictor with the pre-warmed Krebs solution several times until the basal tone 
was reestablished. The ring was then incubated with the extract of different doses for 
30 min and another concentration-response curve to constrictor was repeated. 
5,3.3.3 Relaxant responses of genistein, genistin and the kaempferol glycosides 
on U46619-induced contraction 
In the last series of experiments, the effects of purified individual kaempferol 
glycosides, a mixture of kaempferol glycosides, genistein and genistin were examined 
in U46619-preconstricted artery rings. 
5.3.4 Statistics 
The relaxant effect of the extract and other relaxants was expressed as percentage 
relaxation of the agonist-constricted arterial rings. When drug was given in g/L, IC50 
was calculated as the drug concentration inducing 50% of the maximum inhibition and 
this value was presented together with 95% confidence intervals. When constrictor 
was given in molar per liter, pDj values were calculated as negative log concentration 
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that caused 50% of the maximum contraction. Data were presented as means 士 S.E.M. 
of n experiments. Statistical significance was analyzed by Student's t test or by one 
way A N O V A followed by Newman-Keuls test when more than two treatments were 
compared. A p value less than 0.05 was considered significant. 
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5.4 Results 
5.4.1 Effect of soy leaves butanol extract 
Traces in Figure 5.2 showed the effect of soy leaves butanol extract on the 
isolated rat carotid artery rings preconstricted by 30 n M U46619 (Figure 5.2a), 10 
|xM phenylephrine (Figure 5.2b) or 50 m M extracellular K+ (Figure 5.2c). In 
U46619-preconstrcted endothelium-intact rings, soy leaves butanol extract showed a 
dose-dependent relaxation with an IC50 of 0.19 (0.15-0.23) g/L (n= 5, Figure 5.3). 
The complete relaxation was achieved at a dose of 1 g/L (n= 5). The extract only 
induced partial relaxation of rings preconstricted by phenylephrine and 31 士 5.6o/o 
relaxation was obtained with the extract at 1 g/L (n= 4，Figure 5.3). In contrast, the 
extract had no effect on 50 m M K+-contracted rings (n= 4，Figure 5.3)，but nifedipine 
at 100 n M completely inhibited the high K+ response (n= 4). Besides, the extract 
did not alter contraction induced by active phorbol ester, P M A (1 )iM) in Ca^ -^free 
Krebs solution (n= 4，Figure 5.3). 
5.4.2 Role of endothelium in extract-induced relaxation 
Figure 5.4a showed that the extract induced dose-dependent relaxation in 
U46619-preconstricted rings in both endothelium-intact and -denuded rings with the 
same potency (IC5�: 0.19 (0.15-0.23) g/L, n= 5 with endothelium and 0.16 (0.12-0.20) 
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g/L, n= 4 without endothelium, p >0.05). Similarly, the endothelium was not 
involved in the partial relaxant response to the extract in phenylephrine-
preconstricted rings (n= 4-5, Figure 5.4b). The extract did not relax rings 
contracted by 50 m M K+ regardless the presence or absence of the functional 
endothelium (n= 4，Figure 5.4c). Staurosporine (100 nM), an inhibitor of protein 
kinase C, completely abolished PMA-induced contraction. 
5.4.3 Effect of the soy leaves butanol extract on contractile 
response to prostaglandins 
Since the extract was significantly more potent to relax rings contracted by 
U46619 than phenylephrine, it was worthwhile testing whether the yet-to-be-
identified active components in the extract may act as pharmacological antagonist(s) 
of prostaglandin-induced vasoconstriction. Figure 5.5 showed that pretreatment 
with the extract caused approximately parallel rightward shift of the concentration-
response curve for U46619-induced relaxation and this effect was dose-dependent 
with slight suppression of the maximum relaxation. The pDj values were 8.04 土 
0.02 in control; 7.62 士 0.02 in 0.03 g/L extract, 7.11 土 0.02 in 0.3 g/L extract, and 
7.00 士 0.04 in 1.0 g/L extract (n= 4-5, p < 0.05 compared with the control value, 
Figure 5.5a). The extract also reduced the concentration-dependent contractile 
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responses to PGFja (Figure 5.5b). Traces for the concentration-response curves of 
U46619 were shown in Figure 5.6. In control experiments, glibenclamide was used 
to relax U46619-contracted rings as an antagonist of prostaglandin-induced vascular 
response (n= 4，pDj values = 6.57 土 0.08). 
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Figure 5.2 The representative recordings showing the vascular effect of soy 
leaves butanol extract on the isolated rat carotid arteries with endothelium 
preconstricted by 30 n M U46619 (a), 10 p M phenylephrine (b), and 50 m M IC+ (c). 
The calibration bars apply to all traces. 
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Figure 5.3 The concentration-response curve for the extract-induced effect in 
endothelium-intact rings preconstricted by U46619 (〇，n= 5)，phenylephrine (•，n= 
5)，50 m M K+(•，n= 4) and P M A (•, n= 4). Data are expressed as means 士 S.E.M. 
of n experiments. 
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Figure 5.4 Effect of soy leaves butanol extract in rat carotid arteries pre-
constricted by 30 n M U46619 (a), 50 m M K+ (b) and 10 ^ iM phenylephrine (c) in the 
presence (〇，n= 4-5) and absence of endothelium (•，n= 5-7). Data are expressed 
as means 士 S.E.M. of n experiments. 
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Figure 5.5 (a) Concentration-dependent relaxing effect of soy leaves butanol 
extract on U46619-contracted arterial rings with endothelium (〇�in control; • �0 . 0 3 
g/L; •，0.3 g/L; 1 g/L butanol extract, n= 6 in each case), (b) Concentration-
dependent relaxing effect of soy leaves butanol extract on PGFja-contracted arterial 
rings with endothelium (〇，in control; •，0.3 g/L; 1 g/L butanol extract, n= 4 in 
each case). The rings were incubated with extract at different doses for 30 min 
before the second concentration-response curve was repeated. The contractile 
responses were expressed as percentages of the maximum contraction in the first 
(control) concentration-response curve. Data are expressed as means 士 S.E.M. of n 
experiments. 
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Figure 5.6 (a and b). Traces showing the contractile response of U46619 in the 
absence (a) and in the presence of 0.03 g/L soy leaves butanol extract (b). The 
tissues were incubated with the drugs for 30 minutes before the second dose response 
curves of U46619 (1-500 nM) were constructed. Calibration bars apply to the 
traces. 
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Figure 5.6 (c and d). Traces showing the contractile response of U46619, in the 
presence of 0.3 g/L (c) and 1.0 g/L soy leaves butanol extract (d). The tissues were 
incubated with the drugs for 30 minutes before the second dose response curves of 
U46619 (1-500 nM) were constructed. Calibration bars apply to the traces. 
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5.4.4 Effects of kaempferol glycosides and kaempferol 
The six kaempferol glycosides from the butanol extract, which accounted for 
47.8% (w/w) in it (Table 5.1). The HPLC chromatogram was shown in Figure 5.7. 
In order to search for the responsible components for the extract-induced relaxation, 
the individual glycosides were tested in U46619-preconstrcited endothelium-intact 
rings. Figure 5.8 showed that none of the six kaempferol glycosides affected the 
vessel tone (n= 4-5). In contrast, kaempferol without sugar molecules produced 
concentration-dependent relaxation (IC50： 0.40 (0.35 to 0.45) mg/L, n= 4，Figure 5.9). 
In order to examine further whether a mixture of kaempferol glycosides may have a 
synergestic effect on vessel relaxation, a mixture of kaempferol glycosides was 
prepared according to their relative composition by weight in the extract. This 
mixture did not change the contractile response to U46619 (n= 5, Figure 5.9). 
5.4.5 Effects of genistein and genistin 
The extract also contained genistin and malonyl-genistin, which accounted for 
0.67% and 1.26% of the butanol extract in weight, respectively. A minute amount 
of genistein was also present in the extract. Both agents relaxed the endothelium-
intact rings in a dose-dependent manner with genistein being more potent than 
genistin (pDj values were 5.74 土 0.03 (n= 4) in genistein, 4.09 ±0.19 (n= 4) in 
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genistin (Figure 5.10). Genistein at 10 p M produced near maximum relaxation 
(90.3 士 1.90/0), while this concentration of genistin had no effect. Genistin at 300 





















































































































































































































Table 5.1 Percentage of flavonoids and flavonoid glycosides in soy leaves butanol 
extract 
% in soy leaves butanol 
extract (w/w)  
Kaempferol-3-O-a-L-rhamnopyranosyl (l->2)-|3-D- 5.2 ± 0.1 
glucopyranosyl (1 6)-|3-D-galactopyranoside  
Kaempferol-3-0-(2,6-di-0-a-rhamnopyranosyl)-P- 14.0 士 0.3 
galactopyranoside  
Kaempferol-3-O-digalactopyranoside 5.6 ±0.1 
Kaempferol-3-O-diglucopyranoside 4.4 士 o. 1 
Kaempferol-3-O-a-L-rharmnopyranosyl (l->6)- p-D- 8.2 ± 0.1 
galactopyranoside  
Kaempferol-3-O-rutinoside 10.4 ±0.1 
Genistin 0.7 ±0.1 
Malonyl-genistin 1.3 ±0.1 
Genistein “ 0.0 土 0.0 
Data are expressed as mean 士 S.D. (n= 3) 
Kaempferol glycosides in soy leaves butanol extract (w/w) = 47.8% 
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Figure 5.8 Effects of six kaempferol glycosides on 30 n M U46619-contracted 
endothelium-intact arterial rings (n= 4 in each case). Data are means 士 S.E.M. of n 
experiments. 
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Figure 5.9 Effect of kaempferol (〇，n= 4) and a mixture of kaempferol 
glycosides on U46619-contarcted rings (•’ n= 4). Data are means 土 S.E.M. of n 
experiments. 
116 
驾 100"] • Genistein _ ^ ^ _ 
rH 2 ^ • — — • ~ • 
g o • • Genistin 厂 
！醒 50: / ^ 
, 0 , 1 - J 
W Q-l • ^ ^ ~ • ^ 
I 1 I 1 I M 11| 1~I I I 11 ir | 1~ I I I m i l 1~ I I I | | | | | 
- 7 - 6 - 5 - 4 - 3 
Log [Drug, M; 
Figure 5.10 Effects of genistein and genistin in rat carotid arteries pre-constricted 
by 30 n M U46619 in the presence of endothelium (•, n= 4 in genistein and •, n= 5 
in genistin). Data are means 土 S.E.M. of n experiments. 
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5.5 Discussion 
The present study was the first attempt to examine the vascular effects of soy 
leaves extract and its bioactive ingredients. The present results showed that soy 
leaves butanol extract dose-dependently relaxed the isolated rat carotid arteries. 
The relaxant effect was much greater in rings preconstricted by U46619, a potent 
thromboxane Aj receptor agonist, than by phenylephrine, a selective a-adrenoceptor 
agonist. It is clear that some unknown components contained in the extract possess 
vasorelaxant property. The extract-induced vasorelaxation was independent of the 
presence of the functional endothelium since endothelium removal did not affect the 
relaxing potency, indicating that endothelium-derived vasoactive factors, either 
relaxing or constricting, were not involved. U46619 and phenylephrine contract 
blood vessels via similar mechanisms, depending on the presence of extracellular 
calcium ions. A substantial amount of agoinst-induced Ca^^ influx occured via 
voltage-gated Ca:. channels since nifedipine, a Ca^^ channel antagonist produced 
marked inhibition of agonist-induced vasoconstriction. Protein kinase C activated 
by both diaceylglycerol and intracellular Ca^^ is reported to facilitate Ca^^ entry by 
promoting voltage-gated Ca2+ channel activity. However, the present results rule 
out the possible inhibitory effects of the extract on contractile response induced by 
Ca2+ influx through voltage-gated Ca^^ channels or protein kinase C activation. 
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Firstly, the extract had no effect on the contraction induced by 50 m M K+. It is 
generally believed that one of the major consequences of raising extracellular K+ is to 
open voltage-gated Ca^^ channels by membrane depolarization of the vascular 
smooth muscle. In contrast, nifedipine completely inhibited the high K+-evoked 
contraction. This indicates that the extract does not contain any components that 
may function as antagonists of Ca^^ channels. In endothelium-denuded rings bathed 
in Ca2+-free medium, a slowly developed contractile response can be evoked by 
P M A , exogenous activator of protein kinase C, suggesting that protein kinase C 
stimulation may interact with contractile filaments at the resting cytosolic Ca^^ level 
(Huang 1996). The extract did not alter the PMA-induced contraction, implying 
that inhibition of protein kinase C-mediated pathway was not the mechanism 
responsible for extract-induced relaxation. In control experiments, the protein 
kinase C inhibitor staurosporine totally suppressed PMA-induced response. 
The present results showed that the extract was much more effective in relaxing 
rings preconstricted by 1146619 than phenylephrine, suggesting the possible 
antagonistic action of vasoconstricting prostaglandins. Indeed, the extract at 0.03 
and 0.3 g/L caused parallel right ward shift of the concentration-response curve for 
U46619-induced contraction while the extract at 1 g/L slightly reduced U46619-
induced maximum contraction. In addition, the extract also dose-dependently 
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reduced contractile response to PGFja, another member of vasoconstricting 
prostaglandins. These data suggest that some unidentified components of the 
extract that may act as prostaglandin antagonists, which needs to be further 
investigated. 
Another objective of the present study was to identify the bioactive components 
of the extract. In this regard, six kaempferol glycosides were isolated. It was 
found that these six glycosides accounted for 48% of total extract weight. However, 
none of these six kaempferol glycosides affected U46619-induced contraction. 
Besides, when a mixture of six glycosides was prepared according to their relative 
percentage composition in the extract, no effect could be observed. These results 
clearly showed that kaempferol glycosides were inactive in relaxing the rat carotid 
arteries. In contrast, kaempferol caused concentration-dependent relaxation. If 
kaempferol glycosides can be converted to kaempferol during intestinal absorption 
by losing their sugar moieties, the latter should be able to possess vasorelaxant effect. 
The extract also contained a small amount of genistin (1.26% in weight), but the 
amount of genistein was too little to be quantified by HPLC analysis. Genistin 
caused a dose-dependent relaxation. However, the concentration of genistin at 
35.11 mg/L (calculated from the pD: value of genistin) caused 50% relaxation in 
U46619-induced contraction was much higher than that 1.27 mg/L contained in 0.19 
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g/L extract that cause 50% relaxation in U46619-induced contraction, indicating that 
genistin was not the main ingredient accounting for the observed relaxation induced 
by the extract. The present study was also to examine the effect of genistein, which 
was purchased from Sigma with a purity over 98%. Genistein was a potent relaxant 
against U46619-induced contraction. Even if genistein was formed from genistin, 
this would contribute little to the extract-induced relaxation. 
Taken together, soy leaves extract relaxed the isolated rat carotid arteries pre-
constricted by thromboxane Aj and prostaglandin Fj^. The extract also relaxed the 
arterial rings contracted by phenylephrine albeit to a much less degree. The extract 
(0.03 and 0.3 g/L) caused relaxation indicating that some component(s) in soy leaves 
extract could act as prostaglandin antagonist(s). Lack of effect on contractile 
response to raised extracellular K+ which activates Ca^^ channels, or active phorbol 
ester which activates protein kinase C, indicated that the extract was not comprised 
of any components which may inhibit either voltage-gated Ca^^ channels or protein 
kinase C-dependent cellular mechanism. Kaempferol glycosides account for about 
48% in total extract weight, however, none of these glycosides relaxed preconstricted 
rings, showing that kaempferol glycosides were devoid of vasorelaxant activity. 
These kaempferol glycosides may become kaempferol by the bacteria in the intestine 
(Kuhnau 1976; Hollman and Katan 1999) which then absorbed into the blood and 
121 
relax blood vessels. Lack of a relaxing effect of genistin, although it was contained 
in the extract, on the contraction at doses that fall within the effective dose range of 
the extract. This suggested that genistin was not a responsible ingredient of the 
extract at doses used for vasorelaxation. Further experiments are needed to identify 
the active components that actually account for the vasorelaxant effect of soy leaves 
extract and to examine their vascular action. There is limited information in 
literature regarding the bioactive components of soy leaves even though soy leaves 
are abundantly available. By comparison with soybean, phytoestrogenic agents 
such as genistein is present only in a minute amount in soy leaves. On the other 
hand, soy leaves contains kaempferol glycosides but not in soybean. Therefore, soy 
leaves may be able to use as an effective vasorelaxant. 
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Chapter 6 
Effect of soy leaves on mammary tumor 
6.1 Introduction 
Breast cancer is the most common cancer and the second most frequent cause of 
cancer death in women (Parker et al 1997). Several factors such as genetic, 
ovarian hormonal level, nutrition and life style may play a significant role in the 
development of breast cancer. Epidemiological data suggest that higher intakes of 
soy protein are associated with lower rates of breast cancer (Lee et al 1991; Messina 
et al 1994; W u et al 1998). Some studies support that isoflavones are the major 
component in soybean that are responsible for this cancer preventing ability (Barnes 
1995; Peterson and Barnes 1996). 
6.1.1 Carcinogenesis 
Carcinogenesis, the process of cancer, consists of three stages: initiation, 
promotion and progression. However, the real situation is more complex and the 
stages less distinct. 
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6,1. LI Initiation 
It is believed that proto-oncogenes become oncogene through mutation, which 
occurs when a gene is altered in some way. Most of the time, mutations are 
harmless because they occur in genes that have little effect on cell function. But 
when the mutation occurs in the "right" place in a proto-oncogene, the result is the 
formation of an oncogene. 
Sometimes, mutations occur spontaneously, but more often, they are due to an 
outside influence. Something that causes a mutation is called a mutagen. 
Mutagens that cause cancer are called carcinogens. Examples of carcinogens are 
some pesticides and herbicides and certain industrial chemicals as well as asbestos 
and many chemicals in tobacco. X-rays in a high dose and some viruses cause 
mutation that can result in cancer. 
6.1,1.2 Promotion 
Initiation involves a permanent and irreversible change in the D N A . Once the 
change has occurred and the cell has divided, the message to repeat the process is 
passed on from one generation of cells to the next. Initiation happens very quickly, 
but most initiated cells probably remain dormant, or inactive, until acted on by 
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promoters. Without the action of promoters, initiated cells will not progress to a 
disease stage. 
Promoting agents are not carcinogenic in themselves, that is, they cannot cause 
cancer in non-initiated cells. Promoters induce initiated cells to divide. Initiated 
cells can grow in number more easily than normal cells. The period between 
initiation and the appearance of tumors is one of the least understood aspects of 
tumor development. This period is called the latency period. The latency period 
can be more than twenty years before tumor develop. 
6.1.1.3 Progression 
The final stage of carcinogenesis is progression. At this point, the developing 
tumor is beginning to acquire traits that allow it to grow in size and to invade and 
spread to other tissues. The spreading of cancer cells to other parts of the body is 
metastasis. One very important part of this final stage is angiogenesis, the 
development of new blood vessels. For tumors to grow in size, they need to create 




Soy leaves, not only contains genistein but also its glycosides. Another kind of 
flavonoid glycosides, kaempferol glycosides, which may be beneficial in cancer 
prevention (Dimas et al 2000)，is also present in it. In the present study, the 
anticarcinogenic effect of soy leaves on mammary tumor was investigated using 
female Sprague-Dawley rats as an animal model. 
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6.3 Materials and methods 
6.3.1 Animal 
Female Sprague-Dawley rats were housed (3- 4 rats per cage) in an animal room 
at 25 with 12:12-h light-dark cycles. Fresh semi-synthetic diets were given daily, 
and uneaten food was discarded. Food intake was measured daily and body weight 
was recorded twice a week. The rats were allowed access to food and fluid ad 
libitum. 
All the rats were gavaged with dimethylbenz[a]anthracene ( D M B A ) (Sigma 
Chemical, St. Louis, M O , USA), a carcinogen, at the proestrus or estrus phases, in 
order to diminish the influence of ovarian hormonal level. The amount of D M B A 
gavaged was according to their body weights (80 mg/kg). 
Once the D M B A were gavaged, all the rats (125- 140 g) were randomly divided 
into 2 groups (n= 20). They were fed a semi-synthetic diet, with or without 
supplementation of soy leaves powder (SLP). The method described by Appelt and 
Reicks (1999) was modified and used to prepare the semi-synthetic diet. For the 
control group, diet was prepared by mixing the powdered ingredients (casein, 200 g; 
com oil, 70 g; starch, 509 g; sucrose, 100 g; cellulose, 50 g; mineral mix, 35 g； 
vitamin mix, 10 g; DL-methionine，3 g; and choline bitartrate, 3 g) with 200 m L 
gelatin solution (lOOg/L). For the SLP group, 3 % by weight soy leaves powder 
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(SLP) was mixed with the control diet before setting them in gelatin. Once the 
gelatin had set, the diet was cut into approximately 20 g cubic portions and stored 
frozen (-20 °C). 
The percentage dietary fiber content in the control and SLP groups were 4.6 土 
0.2 and 5.6 士 0.3 respectively (the total dietary fiber content was determined 
according to the official method described in A O A C 991.43). All the rats were 
checked weekly to monitor their body weights and palpable tumors. 
6.3.2 Determination of estrus cycle 
During the reproductive cycle of the mammalian female, the secretion of 
estrogens and progesterone varies with the phases of the ovarian cycle (Lu et al 
1979). The estrogen levels are low after ovulation (estrus phase) and remain at low 
levels until diestrus when a new set of ovarian follicles begins to mature. By the 
end of the diestrus phase, serum estrogen levels are significantly elevated and 
continue to rise until a peak is reached just prior to ovulation (proesturs phase) (Shin 
and Lee 1978). This in turn produces characteristic changes in the epithelial lining, 
and in the secretory and muscular activities of the female reproductive tract. In 
general, the effect of estrogens is to induce vaginal comification and progesterone 
stimulates mucification. 
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A small amount of saline (0.9% NaCl) was flushed into and out of the vagina 
for 2 to 3 times by using a pasteur pipette. The washing was then spread onto a 
glass slide and dried in air. Then, it was fixed in methanol and air dried completely. 
The slide was dipped into 0.1% methylene blue solution for 3 minutes. The excess 
methylene blue was washed away by tap water. Finally the slide was dried and 
mounted. 
The four phases in the estrus cycle are proestrus, estrus, metestms and diestrus. 
In the proestrus and estrus phases, the vaginal smear consisted of mainly nucleated 
polygonal epithelial cells and comified squamous epithelial cells respectively. 
However, in the metestrus and diestrus, the vaginal smear consisted of mainly 
leucocytes. Figure 6.1a and b showed the vaginal smears in proestrus and diestrus 
phases respectively. 
6.3.3 Statistics 
Chi-square test was used for statistical evaluation of differences for the 
incidence rate and number of tumors between groups at the same week (SigmaStat 
version 2.01, SigmaStat Advisory Statistical Software, M O , USA). 
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Figure 6.1 Vaginal smears of the rats in proestrus (a) and diestrus (b) phases. 
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6.4 Results 
6.4.1 Incident rate of tumor induction 
Figure 6.2 showed the incident rate of tumor induction at different time points 
during the entire experimental period. No significant differences were found 
between the two groups at different time points. 
6.4.2 Number of tumor induced 
Figure 6.3 showed the cumulative number of tumors induced during the entire 
experimental period. No significant differences were found between two groups at 
different time points. 
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Figure 6.2 Effect of soy leaves supplementation on mammary tumor (n= 20 
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Figure 6.3 Effect of soy leaves on number of tumors induced (n= 20 in each 
group). SLP: Soy leaves powder 
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6.5 Discussion 
Epidemiological data suggested that soybean may be beneficial in the 
prevention of certain cancers (Lee et al. 1991; Wu et al. 1998). It is believed that 
genistein and its glycosides are the active components in soybean which are 
responsible for this beneficial effect. 
The growth of breast tumor cells is partly regulated in vivo through the action of 
estrogen. Estrogen may binds to and activates the cytosolic estrogen receptor (ER). 
Activated E R then translocates to the nucleus and initiates specific transcriptional 
events via its interaction with estrogen response elements on D N A . Estrogen can 
increase the levels of both growth factor receptors and their ligands. 
Genistein, with a similar structure to estrogen, was proposed to have a weak 
estrogenic activity and can compete with estrogen for binding to the nuclear estrogen 
receptor (Martin et al 1978). Setchell et al (1984) suggest that genistein may 
inhibit tumor cell growth by an antiestrogenic mechanism through competition with 
E
2
 for occupancy of the estrogen receptor (ER). Some studies review that genistein 
may also prevent tumor formation through the mechanisms of protein tyrosine kinase 
inhibition, topoisomerase II inhibition and inhibition of oxidation (Barnes and 
Peterson 1995b; Constantinou and Huberman 1995; Peterson 1995). 
Although soy leaves contains genistein and its glycosides, their content were not 
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as high as that present in soybean (Chapter 2，Table 2.4). 
The present study suggested that supplementation of 3 % soy leaves powder in 
the diet could not decrease the incident rate of mammary tumor and the number of 
tumors induced in female Sprague-Dawley rats. This is probably because the 
amount of genistein and its glycosides present in soy leaves were not enough to 




Soybean {Glycine max L. Merr.) is one of the major food sources in China. It 
is usually consumed in the forms of soymilk and "tofli" (bean curd). Recently, 
many studies have been carried out to examine the health benefits of soybean. It 
was believed that isoflavone was the active component in soybean that is responsible 
for these health benefits. But there were no studies about the health benefits or 
chemical composition of soy leaves. In the present study, six different kaempferol 
glycosides were isolated from soy leaves. They are kaempferol-3-0-a-L-
rhamnopyranosyl( 1 —2)-p-D-glucopyranosyl( 1 -^6)-(3-D-galactopyranoside, 
kaempferol-3-0-(2,6-di-0-a-rhamnopyranosyl)-P-galactopyranoside, kaempferol-3-
0-digalactopyranoside, kaempferol-3-O-diglucopyranoside, kaempferol-3-0-a-L-
rharmnopyranosyK 1 ->6)-p-D-galactopyranoside and kaempferol-3-O-rutinoside. It 
was found that soy leaves also contained genistein, a kind of isoflavone, and its 
glycosides. 
By using hamster as an animal model, supplementation of 3 % soy leaves 
powder (SLP) or 3 % soy leaves ethanol extract (SLEE) in their diet could 
significantly lower the ratios of non-HDL-C to HDL-C, an indicator in determining 
the risk of cardiovascualr diseases. The higher the ratio, the greater the chance of 
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getting cardiovascualr diseases. The excretion of neutral and acidic sterols were 
generally higher in these two groups. The decrease in the ratio of non-HDL-C to 
HDL-C in the SLP and SLEE groups implied that soy leaves supplementation in the 
diet could decrease the risk of cardiovascular diseases. 
Soy leaves butanol extract showed weak antioxidative activity in Cu2+-mediated 
oxidation of human low-density lipoprotein (LDL) in vitro while all the six 
kaempferol glycosides showed no antioxidative activity on human LDL. However, 
all the six kaempferol glycosides showed strong antioxidative activities on inhibition 
of erythrocytes haemolysis. The inhibition of erythrocytes haemolysis was in a 
dose-dependent manner. The present experimental results showed that the 
antioxidants in soy leaves may be able to decrease the oxidative stress. The present 
study suggest that the major antioxidant present in soy leaves which is responsible 
for the protection of L D L from Cu^^-mediated oxidation has not been isolated. 
Further studies should be carried out to isolate unknown antioxidant(s). 
In the blood vessel relaxing experiments, soy leaves butanol extract relaxed 
artery rings pre-constricted by U46619 or PGFj^ in a dose-dependent manner and this 
effect was independent of endothelium. The extract also inhibited the concentration-
contraction curve to U46619 with slight reduction of the maximum contraction. The 
extract produced partial relaxation of phenylephrine (10 nM)-preconstricted both 
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endothelium-intact and -denuded rings. In contrast, the extract had no effect on the 
contractile response to 50 m M extracellular K+. None of the six kaempferol 
glycosides affected vessel tension induced by U46619. A mixture of kaempferol 
glycosides prepared according to their relative composition in the extract had no effect 
either. Genistein induced a greater concentration-dependent relaxation than genistin. 
The present results indicated that soy leaves butanol extract caused endothelium-
independent relaxation in rat carotid artery rings. The six kaempferol glycosides, 
accounting for -48% the extract in weight, were not the ingredients responsible for the 
extract-induced relaxation. Genistein and genistin also caused relaxation, however, the 
dose range was beyond that of the extract causing relaxation. Further experiments are 
needed to identify the active components that actually account for the vasorelaxant 
effect of soy leaves extract and to examine their vascular action. 
In the experiment of tumor induction, supplementation of 3 % soy leaves powder 
in the diet could neither decrease the incidence rate nor the number of tumors 
induced. The present study indicated that soy leaves might not be able to prevent 
the development of mammary tumor or the amount of active components, genistein 
and its glycosides, in soy leaves were not enough to produce an inhibitory effect on 
tumor development. 
In conclusion, soy leaves may possess some beneficial effects in humans 
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through the actions of modifying the lipoprotein profile to lower risk of 
cardiovascular disease, scavenging of the free radicals to decrease the oxidative 
stress and dilating the arteries to decrease the risks caused by hypertension. 
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